Original Article
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
N Engl J Med 2003; 348:15-23January 2, 2003DOI: 10.1056/NEJMoa020696
- Abstract
Background
In patients with multiple sclerosis, inflammatory brain lesions appear to arise from autoimmune responses involving activated lymphocytes and monocytes. The glycoprotein α4 integrin is expressed on the surface of these cells and plays a critical part in their adhesion to the vascular endothelium and migration into the parenchyma. Natalizumab is an α4 integrin antagonist that reduced the development of brain lesions in experimental models and in a preliminary study of patients with multiple sclerosis.
Methods
In a randomized, double-blind trial, we randomly assigned a total of 213 patients with relapsing–remitting or relapsing secondary progressive multiple sclerosis to receive 3 mg of intravenous natalizumab per kilogram of body weight (68 patients), 6 mg per kilogram (74 patients), or placebo (71 patients) every 28 days for 6 months. The primary end point was the number of new brain lesions on monthly gadolinium-enhanced magnetic resonance imaging during the six-month treatment period. Clinical outcomes included relapses and self-reported well-being.
Results
There were marked reductions in the mean number of new lesions in both natalizumab groups: 9.6 per patient in the placebo group, as compared with 0.7 in the group given 3 mg of natalizumab per kilogram (P<0.001) and 1.1 in the group given 6 mg of natalizumab per kilogram (P<0.001). Twenty-seven patients in the placebo group had relapses, as compared with 13 in the group given 3 mg of natalizumab per kilogram (P=0.02) and 14 in the group given 6 mg of natalizumab per kilogram (P=0.02). The placebo group reported a slight worsening in well-being (a mean decrease of 1.38 mm on a 100-mm visual-analogue scale), whereas the natalizumab groups reported an improvement (mean increase of 9.49 mm in the group given 3 mg of natalizumab per kilogram and 6.21 mm in the group given 6 mg of natalizumab per kilogram).
Conclusions
In a placebo-controlled trial, treatment with natalizumab led to fewer inflammatory brain lesions and fewer relapses over a six-month period in patients with relapsing multiple sclerosis.
Media in This Article
Figure 1
Cumulative Mean Number of New Gadolinium-Enhancing Lesions on MRI in Each Group during Treatment.Table 1
Base-Line Characteristics of the Patients.Article Activity
- Article
Multiple sclerosis is a leading cause of chronic neurologic disability.1 Several new therapies have been introduced in the past decade,2-5 but additional effective treatments are needed to slow disease progression and reduce disability. The pathological hallmark of multiple sclerosis is multiple foci of inflammation and demyelination within the white matter of the central nervous system. The formation of these lesions may involve lymphocytes and monocytes that gain access to the brain parenchyma from the circulation by first adhering to vascular endothelial cells in regions of inflammation.6 The glycoprotein α4β1 integrin, also known as very late antigen 4, or VLA-4, is expressed on the surface of lymphocytes and monocytes and is an important mediator of cell adhesion and transendothelial migration, as well as a regulator of immune-cell activation within inflamed tissue.7,8
Brain lesions in patients with multiple sclerosis are readily detected with T2-weighted magnetic resonance imaging (MRI). New lesions with features of inflammation can be detected by gadolinium-enhanced T1-weighted MRI,9-12 and this approach has been used to assess disease activity in clinical trials.
Treatment with an antibody against α4 integrin reduced signs of disease activity and inflammation in mice with experimentally induced allergic encephalomyelitis, a rodent model of multiple sclerosis.13-15 Natalizumab (Antegren, Elan Pharmaceuticals and Biogen), a humanized monoclonal antibody, is an α4 integrin antagonist in a class of agents known as selective adhesion-molecule inhibitors. In a small, placebo-controlled study of patients with multiple sclerosis, natalizumab reduced the frequency of new gadolinium-enhancing lesions.16 Because the patients received only two infusions one month apart, the longer-term effects of antagonism of α4 integrin on the formation of brain lesions and various clinical outcomes are unknown. Therefore, we conducted a randomized, placebo-controlled trial of six months of treatment with natalizumab in patients with relapsing multiple sclerosis.
Methods
Patients
Twenty-six clinical centers in the United States, Canada, and the United Kingdom enrolled 213 patients from September 1999 until May 2000. The protocol was reviewed and approved by central and local ethics committees. Before providing informed consent, all patients were told by the investigator of the alternative effective therapies available to them, and any who wished to try one of these therapies were encouraged to do so. All patients gave written informed consent. The study was overseen by an independent data and safety monitoring committee. The study data were gathered by the investigators and by an independent organization (PPD Development); the data were held and analyzed by Elan and Biogen. The principal investigators on the writing team had access to all data.
Eligible patients were 18 through 65 years of age, met the criteria of Poser et al. for clinically definite or laboratory-supported definite multiple sclerosis17 — either relapsing–remitting or secondary progressive multiple sclerosis18 — had had at least two relapses within the previous two years, had a base-line score on the Kurtzke Expanded Disability Status Scale19 between 2 and 6.5 (scores can range from 0 to 10, with higher scores indicating more severe disease), and had had a minimum of three lesions on T2-weighted MRI of the brain. Patients were ineligible if they had received immunosuppressive or immunomodulating treatments within the preceding 3 months or had had a relapse or received systemic corticosteroids within the preceding 30 days.
Study Design and Randomization
Patients were randomly assigned to one of three treatments — 3 mg of natalizumab per kilogram of body weight, 6 mg of natalizumab per kilogram, or placebo — with use of a computer-generated block randomization schedule. Randomization was performed centrally by PPD Development. Patients received an intravenous infusion every 28 days for 6 months and were then monitored for an additional 6 months for adverse effects. Neither the study personnel nor the patients were aware of the blinded treatment assignments.
Study Procedures and End Points
Unenhanced proton-density, T2-weighted MRI and gadolinium-enhanced T1-weighted MRI scans were obtained during the screening phase (one month before randomization), immediately before each treatment (months 0 through 5), and one month after the last treatment (month 6). Follow-up scans were obtained at months 9 and 12. Forty-six contiguous, 3-mm-thick, axial slices were acquired through the brain. MRI analysis was performed by a single center whose members were unaware of the patients' treatment and history. Two experienced clinicians identified the lesions on hard-copy images after reaching a consensus.
The primary outcome measure was the number of new gadolinium-enhancing lesions over the six-month treatment period, defined as the period following the first infusion (month 1) to one month after the last infusion (month 6). Other MRI outcomes included the number of persistent enhancing lesions (enhancing lesions that had also been present on the previous monthly scan); the volume of enhancing lesions (measured with use of a semiautomated method20); the number of new active lesions (the number of new enhancing lesions plus the number of new or newly enlarging, nonenhancing lesions on T2-weighted MRI); and the number of scans showing one or more new enhancing lesions.
Secondary and tertiary clinical end points included the frequency of relapse, changes in the scores on the Kurtzke Expanded Disability Status Scale, and patients' own assessments of well-being. All adverse events were recorded. Patients were examined at scheduled intervals — and at unscheduled visits in the case of a suspected relapse — by the treating and evaluating neurologists, both of whom were unaware of the patients' treatment assignments. The treating neurologist obtained a medical history and, at each monthly visit, conducted physical and neurologic examinations and recorded adverse events. The evaluating neurologist assessed each patient's neurologic status at quarterly intervals and at unscheduled visits and assigned each a score on the Expanded Disability Status Scale without knowledge of the patient's history or prior scores.
An objective relapse, determined by the evaluating neurologist, was defined as the occurrence of an acute episode of new or worsening symptoms of multiple sclerosis that lasted at least 48 hours after a stable period of at least 30 days and was accompanied by an increase from base line of at least one point in the score on the Expanded Disability Status Scale, at least one point on two functional system scores, or at least two points on one functional system score. Neurologic symptoms that did not meet the above criteria for relapse but were judged by the treating neurologist to constitute a relapse were also recorded (and included in the total number of relapses).
On a visual-analogue scale, patients marked a point along a 100-mm line that reflected their assessment of overall well-being at base line and after three and six months of treatment. Higher scores reflected a greater sense of well-being.
Serum samples were collected at each visit and analyzed for binding antibodies against natalizumab with use of an enzyme-linked immunosorbent assay. Serum levels of natalizumab and the extent of α4 integrin–receptor occupancy by natalizumab were measured in a subgroup of 12 to 14 patients per treatment group before each infusion and 2 hours, 24 hours, and one, two, and three weeks after the first and last infusions. Patients were followed clinically to month 12. Patients who discontinued treatment prematurely were encouraged to return for follow-up assessments.
Statistical Analysis
Estimates of sample size were based on the number of new enhancing lesions observed during the first 12 weeks after the first infusion in a previous clinical trial of natalizumab.16 Using methods based on the Wilcoxon–Mann–Whitney statistic21 appropriate for a two-group comparison at a two-sided level of significance of 5 percent, we calculated that approximately 73 patients were needed in each group for the study to have 80 percent power.
The primary comparison of the number of new enhancing lesions was evaluated with use of the Wilcoxon–Mann–Whitney rank-sum test. Given the short-term effects of corticosteroids on gadolinium-enhancing lesions, MRI scans obtained from patients who had received systemic corticosteroids within the previous 30 days were discarded and treated as missing values to avoid confounding of the efficacy analyses. We imputed these missing values and those due to one or more scans' not being performed by replacing the missing value with the average number of lesions on available scans obtained at months 1 through 6 for that patient. This type of imputation was performed for the primary end point as well as all other end points involving lesion counts during the six-month treatment phase. According to the prespecified analysis, the imputation of lesion volume and scores on the Expanded Disability Status Scale followed the principle of the last observation carried forward. No imputation method was specified for the analyses of relapses at any point during the study and MRI data after month 6; therefore, missing data were excluded from these analyses during the corresponding period.
Demographic and base-line clinical characteristics were compared with use of a two-way analysis of variance, with site and group included as independent variables, for continuous data and Fisher's exact test for categorical data. Base-line MRI characteristics were compared with use of the Kruskal–Wallis test. For analysis of the end points, we used the Wilcoxon–Mann–Whitney rank-sum test for all analyses involving lesion counts, including the primary end point. Averaged scores were assigned to tied rank values. Lesion volumes, the mean percentage of scans showing activity, and changes from base line in the scores for the Expanded Disability Status Scale and visual-analogue scale were analyzed with the use of two-way analysis of variance, with site and group included as independent variables. Fisher's exact test was used to compare the proportions of patients in each group who had one or more relapses. When no data were available to determine whether a relapse could be objectively confirmed, that relapse was excluded from the analysis of objective relapses.
All analyses followed the intention-to-treat principle. All reported P values are two-tailed. No interim analyses were performed before the primary end point was analyzed.
Results
Among the 213 patients, 71 were randomly assigned to receive placebo, 68 to receive 3 mg of natalizumab per kilogram, and 74 to receive 6 mg of natalizumab per kilogram. There were no significant differences in clinical or MRI characteristics at base line (Table 1Table 1
Base-Line Characteristics of the Patients.).All the patients received at least one dose of the assigned drug. Five patients in the placebo group, five in the group given 3 mg of natalizumab per kilogram, and eight in the group given 6 mg of natalizumab per kilogram discontinued treatment prematurely. Of these patients, three in the placebo group, four in the 3-mg group, and one in the 6-mg group remained in the study until the end of the treatment period. In the analysis of the primary end point during the treatment period, 6.3 percent of the values were imputed: the distribution of imputed values was 8.2 percent of those in the placebo group, 2.9 percent of those in the 3-mg group, and 7.7 percent of those in the 6-mg group.
Primary Outcome
The placebo group had a mean of 9.6 new gadolinium-enhancing lesions per patient during the treatment period. The corresponding means were 0.7 in the group given 3 mg of natalizumab per kilogram (P<0.001) and 1.1 in the group given 6 mg of natalizumab per kilogram (P<0.001) (Table 2Table 2
Overall MRI Findings during the Six Months of Treatment and during Six Months of Follow-up. and Figure 1Figure 1Cumulative Mean Number of New Gadolinium-Enhancing Lesions on MRI in Each Group during Treatment.). There was no significant difference in values between the two natalizumab groups. A sensitivity analysis, performed with and without imputed values (the latter including actual counts on MRI scans obtained within 30 days after corticosteroid treatment), yielded consistent, statistically significant results.The subgroup of patients with relapsing–remitting multiple sclerosis had significantly fewer new enhancing lesions with either dose of natalizumab than with placebo (mean, 12.1 in the placebo group, as compared with 0.6 in the group given 3 mg of natalizumab per kilogram [P<0.001] and 0.6 in the group given 6 mg of natalizumab per kilogram [P<0.001]). The subgroup of patients with secondary progressive multiple sclerosis had fewer new enhancing lesions with natalizumab than with placebo, and the difference was statistically significant in the group given 3 mg of natalizumab per kilogram (mean, 5.4 in the placebo group, as compared with 1.0 in the group given 3 mg of natalizumab per kilogram [P=0.005] and 2.0 in the group given 6 mg of natalizumab per kilogram [P=0.08]).
Secondary MRI Outcomes
There was a marked reduction in the number of persistent enhancing lesions, the number of new active lesions, the total volume of enhancing lesions, and the percentage of scans showing activity in each natalizumab group as compared with the placebo group (Table 2).
Clinical Outcomes
During the six-month treatment period, 36 relapses were reported in 27 of the 71 patients in the placebo group (38 percent), as compared with 18 in 13 of the 68 patients receiving 3 mg of natalizumab per kilogram (19 percent, P=0.02) and 15 in 14 of the 74 patients receiving 6 mg of natalizumab per kilogram (19 percent, P=0.02). Using the objective criteria, we identified 18 relapses in 15 patients in the placebo group (21 percent), as compared with 3 in 3 patients receiving 3 mg of natalizumab per kilogram (4 percent, P=0.004) and 8 in 8 patients receiving 6 mg of natalizumab per kilogram (11 percent, P=0.11). Sensitivity analyses were performed in which patients with data missing were counted as either having had a relapse or not having had a relapse; all three approaches yielded consistent results. More patients in the placebo group than in either of the natalizumab groups received corticosteroid treatment (using the permitted regimen of 1 g of intravenous methylprednisolone per day for three or five days) for relapse: 22 of 27 (81 percent), as compared with 5 of 13 in the group given 3 mg of natalizumab per kilogram (38 percent, P<0.001) and 7 of 14 in the group given 6 mg of natalizumab per kilogram (50 percent, P=0.002) (Table 3Table 3
Relapses during and after Treatment.).The visual-analogue scores of well-being at month 6 were compared with base-line scores. The placebo group reported a slight worsening (mean decrease of 1.38 mm on a 100-mm scale), whereas the group given 3 mg of natalizumab per kilogram and that given 6 mg of natalizumab per kilogram reported an improvement (mean increase, 9.49 mm [P=0.04] and 6.21 mm [P=0.03], respectively). No significant changes in the scores on the Expanded Disability Status Scale were observed in any group during the six-month treatment period (mean increase of 0.03 in the placebo group and mean decrease of 0.14 and 0.03 in 3-mg and 6-mg groups, respectively).
Pharmacodynamics
Total white-cell counts increased in both natalizumab groups within the first month of treatment and remained elevated until month 7 in the group given 3 mg of natalizumab per kilogram and month 8 in the group given 6 mg of natalizumab per kilogram. There were increases in the lymphocyte, monocyte, and eosinophil counts in both natalizumab groups, but the mean values were not beyond the normal range and returned to base line by month 9. There was no increase in neutrophil counts.
Binding antibodies against natalizumab developed in 15 patients in the natalizumab groups (11 percent) — 13 during the treatment period and 2 during the post-treatment follow-up period. Pharmacokinetic analysis showed that serum levels of natalizumab were proportional to the dose given. Patients who received 3 mg of natalizumab per kilogram had more than 80 percent saturation of the α4 integrin receptors on peripheral-blood leukocytes during the treatment period; receptor occupancy was approximately 90 percent and was more prolonged in those receiving 6 mg of natalizumab per kilogram.
Safety and Tolerability
Similar numbers of patients in each group had adverse events during treatment (Table 4Table 4
Adverse Events during Treatment.). Eleven serious adverse events occurred in seven patients in the placebo group, five serious events occurred in five patients who were receiving 3 mg of natalizumab per kilogram, and four such events occurred in three patients who were receiving 6 mg of natalizumab per kilogram. Four of these events were considered to be immune-mediated and related to the study drug. One patient who was receiving 3 mg of natalizumab per kilogram had an anaphylactoid reaction with urticaria and bronchospasm, which was rapidly reversed with antihistamines and corticosteroids. There were three reports of serum sickness, one in each group. Only one of these events was accompanied by a change in complement levels, and all three occurred at a single study site. These events complicated fewer than 1 in 250 infusions. Treatment was discontinued because of an adverse event in three patients in the placebo group, four in the group given 3 mg of natalizumab per kilogram, and three in the group given 6 mg of natalizumab per kilogram. One patient in the placebo group died of pleural carcinomatosis complicated by hemothorax.Post-Treatment Follow-up
When the values obtained at month 9 and month 12 were combined, the number of new enhancing lesions and scans showing activity were similar in all three groups (Table 2). After treatment, there was no significant difference among the three groups either in the total number of relapses or in those objectively confirmed (Table 3).
Discussion
Our study provides MRI and clinical evidence that selective inhibition of α4 integrin–mediated adhesion and migration of leukocytes is an effective approach to the treatment of multiple sclerosis. The α4 integrin–specific humanized monoclonal antibody natalizumab suppressed the formation of gadolinium-enhancing inflammatory brain lesions over the six-month treatment period. This effect was evident one month after the first infusion and was sustained throughout the treatment period. The reduction in the formation of lesions was approximately 90 percent at a dose of both 3 mg per kilogram and 6 mg per kilogram and was thus greater than the reduction of 50 to 80 percent reported with the β-interferons and the reduction of approximately 30 percent reported with glatiramer acetate.3,22,23
Although the intent of our study was not to demonstrate that natalizumab affected clinical outcomes, treatment nevertheless resulted in a significant reduction in the frequency of relapse and an increased perception of well-being among the patients. The magnitude of the reduction in both total and objectively confirmed relapses exceeded that of the currently approved treatments for multiple sclerosis, which is approximately 30 percent.2-5 Just as important, although new lesions developed on MRI and relapses recurred after treatment ended, there was no rebound above the level seen in patients who received placebo.
The improved perception of well-being among natalizumab-treated patients should be interpreted with caution, since the visual-analogue scale used to assess well-being has not been widely used. If confirmed, this finding may reflect the decreased frequency of relapses and severity of fatigue and the increased clinical stability associated with natalizumab therapy. Monthly infusions of natalizumab for six months were well tolerated and were associated with a safety profile similar to that of placebo. There was a trend toward an increased rate of infections in the natalizumab-treated patients, the clinical significance of which is unclear. The effects of α4 integrin blockade on human adaptive responses are unknown. Ongoing longer-term studies of natalizumab will provide more definitive data.
Natalizumab binds to α4 integrin and is an antagonist of integrin heterodimers containing the α4 integrin subunit. One such heterodimer is α4β1 integrin, which is expressed on the surface of activated lymphocytes and monocytes — cells that have been implicated in the pathogenesis of acute inflammatory lesions and the breakdown of the blood–brain barrier in patients with multiple sclerosis.24,25 Our results provide evidence of a role of α4 integrin — and the immune cells that express it — in the pathogenesis of acute inflammatory lesions in patients with multiple sclerosis. The increase in circulating lymphocytes in patients treated with natalizumab is consistent with a mechanism involving the antagonism of α4 integrin–dependent adhesion of leukocytes that migrate to regions of inflammation. Binding of natalizumab to α4β1 integrin may also inhibit the activation of T lymphocytes or eliminate autoreactive T lymphocytes, and both doses of natalizumab were associated with near-saturation of the α4β1 integrin receptor. The reduction in the number of new enhancing lesions was evident after one month of treatment, suggesting that natalizumab acts rapidly to prevent the development of lesions.
In summary, natalizumab had beneficial effects on clinical and imaging outcomes in patients with relapsing multiple sclerosis. Therapy was well tolerated during the six-month trial. Promising results with this agent have also been obtained in a randomized controlled trial of patients with Crohn's disease.26 Although our results are encouraging, longer-term data are needed. The effect of natalizumab on the progression of disability and its effect in direct comparison with existing therapies are not yet known.
Sponsored by Elan Pharmaceuticals, South San Francisco, California, and Biogen, Cambridge, Mass.
Dr. Miller has reported receiving grant support from Elan, Schering, and Biogen; honorariums for giving expert advice to Biogen, Wyeth, and Bristol-Myers Squibb; and lecture fees from Serono. Dr. Khan has reported receiving grant support or honorariums from Elan, Teva Neuroscience, Biogen, Serono, and Berlex. Dr. Sheremata has reported receiving grant support from Elan, Teva Neuroscience, Serono, and Biogen. Dr. Blumhardt has reported receiving honorariums from Serono, Teva Neuroscience, and Bayer for giving lectures and expert advice. Dr. Rice has reported receiving grant support from Elan and honorariums from Elan for giving expert advice. Dr. O'Connor has reported receiving grant support from Elan, Biogen, Athena Neurosciences, Aventis, Berlex, Serono, Teva Neurosciences, Angiotech, and Amgen. Dr. Dalton has reported receiving salary support from Elan (through a grant held by the Institute of Neurology) to analyze the MRI data. The MRI group at the Institute of Neurology is also supported by the Multiple Sclerosis Society of Great Britain and Northern Ireland.
We are indebted to Drs. Kenneth Johnson, Stephen Donoghue, and Carol Greenlees for their valuable contributions during the conduct of this study; to Dr. Michael Panzara for many helpful suggestions and enthusiastic support during the preparation of the manuscript; to Dr. Alfred Sandrock for helpful comments; and to Dr. Charles Davis, Donald Bennett, Frances Lynn, and Minhua Yang for statistical advice and analysis.
Source Information
From the Institute of Neurology, London (D.H.M., C.M.D., K.A.M.); Wayne State University School of Medicine, Detroit (O.A.K.); the University of Miami School of Medicine, Miami (W.A.S.); University Hospital, Nottingham, United Kingdom (L.D.B.); the London Multiple Sclerosis Clinic, London, Ont., Canada (G.P.A.R.); Elan Pharmaceuticals, San Francisco (M.A.L., A.J.W.-H.); and St. Michael's Hospital, University of Toronto, Toronto (P.W.O.).
Address reprint requests to Dr. Miller at the Department of Neuroinflammation, Institute of Neurology, Queen Sq., London WC1N 3BG, United Kingdom, or at d.miller@ion.ucl.ac.uk.
Members of the International Natalizumab Multiple Sclerosis Trial Group are listed in the Appendix.
Appendix
In addition to the authors, the following investigators participated in the International Natalizumab Multiple Sclerosis Trial (principal investigators are in boldface type): Institute of Neurology, London (MRI Analysis Center) — G.J. Barker, D.G. MacManus, C. Webb, C. Middleditch, S. Lewis, T. Pepple, E. Riddle, C. Coombs; University of California at Davis, Sacramento — M. Agius, D. Richman, J. Adams, M. Buonocore; University of Nebraska Medical Center, Omaha — J. Al-Omaishi, K. Markopoulou, K. Healey, P. Sorensen; Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom — D. Bates, J. Forsyth, J. Curlis, P. English; University Hospital Queens Medical Centre, Nottingham, United Kingdom — V. Orpe, T. Jaspen; University of Washington, Seattle — J. Bowen, M. Chang, H. Lew, M. Burke, T. Richards; Mayo Clinic, Scottsdale, Ariz. — J.L. Carter, D. Dodick, J. Takata, M. Malikowski, K. Nelson; Washington University School of Medicine, St. Louis — D.A.H. Cross, J. Trotter, D. Derrington, J. Lauber, C. Martinez, G. Foster, T. Conturo; University of British Columbia, Vancouver, Canada — V. Devonshire, J. Oger, L. Wang, W. Morrison, L. Costley; North Staffordshire Royal Infirmary, Stoke on Trent, United Kingdom — C. Hawkins, C. Mathews, C. Gibson; Hospital for Joint Diseases, New York — J. Hebert, I. Rozentsvit, L. Capolino, J.P. Kelly; Carolinas Medical Center, Charlotte, N.C. — M. Kaufman, S. Putman, A. Diedrich, R. Follmer, S. Dombrowski, C. Graves, B. Harwick; Wayne State University, Detroit — A.C. Tselis, M. Din, C. Caon, M. Cochran, Z. Latif, R.P. Lisak, M. Zvartau-Hinds; Foothills Hospital, Calgary, Alta., Canada — L. Metz, J. Scott, D. Patry, M. Yeung, J. Heuser, C. Wallace, S. Curtis; Maimonides Medical Center, Brooklyn, N.Y. — A. Miller, E. Drexler, M.J. Keilson, K. Bruining, A. Schneider, R. Wolintz, L. Sciarra, H. Oltazewska; Rocky Mountain Multiple Sclerosis Center, Englewood, Colo. — R.S. Murray, A. Bowling, R.E. Kramer, K. Bracht, C. O'Brien, L. Seeberger, J. Leitch, E. Prenger, R. Gagnon; St. Michael's Hospital, Toronto — M. Hohol, T. Gray, E. Viara, B. Gray, L. Lewin, J. Rainford; Radcliffe Infirmary, Oxford, United Kingdom — J. Palace, A. Cavey, V. Moody; Texas Neurology, Dallas — J.T. Phillips, A. Martin, D. Hietzman, S. O'Leary, J. Phillips, M. Newsome; Lehigh Valley Hospital, Allentown, Pa. — A. Rae-Grant, J.E. Castaldo, G. Mackin, N.J. Eckert, E. Shoemaker, L. Fowler-Blatt; University of Chicago, Chicago — A. Reder, B. Arnason, A. Noronha, P. Manning, V. Edmonds, B. Jamison, R. Ladsaria; London Health Science Center, London, Ont., Canada — P. Mandalfino, D. Wingerchuk, M. Nicolle, M. Hopkins, D. Lee, E. Buchner, K. Kennedy; Guy's Hospital, London — M. Sharief, K. Wilson, S. Soudain, J. Bingham, P. Graves; University of Miami School of Medicine, Miami — A. Minegar, M. Martinez, G. Calabro, S. Falcone; Ninewells Hospital, Dundee, United Kingdom — R. Swingler, S. Wilson, W. Milne; Yale University School of Medicine, New Haven, Conn. — T. Vollmer, M.A. Rizzo, M. Carrithers, G. Blonco, H. Sarofin; Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom — C. Young, L. Owens, C. Dickinson.
- References
References
1
Compston DAS, Matthews WB, McDonald WI, Ebers G, Wekerle H, Lassmann H. McAlpine's multiple sclerosis. 3rd ed. Edinburgh, Scotland: Churchill Livingstone, 1998.
2
IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group
Web of Science | Medline3
Jacobs LD ,Cookfair DL ,Rudick RA , et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294[Erratum, Ann Neurol 1996;40:480.]
CrossRef | Web of Science | Medline4
Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis Study Group
CrossRef | Web of Science | Medline5
Johnson KP ,Brooks BR ,Cohen JA , et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45:1268-1276
CrossRef | Web of Science | Medline6
Hynes RO . Integrins: a family of cell surface receptors. Cell 1987;48:549-554
CrossRef | Web of Science | Medline7
Frenette PS ,Wagner DD . Adhesion molecules -- part I. N Engl J Med 1996;334:1526-1529
Full Text | Web of Science | Medline8
Frenette PS ,Wagner DD . Adhesion molecules -- part II: blood vessels and blood cells. N Engl J Med 1996;335:43-45
Full Text | Web of Science | Medline9
Thompson AJ ,Kermode AG ,Wicks D , et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62
CrossRef | Web of Science | Medline10
Harris JO ,Frank JA ,Patronas N ,McFarlin DE ,McFarland HF . Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991;29:548-555
CrossRef | Web of Science | Medline11
Thompson AJ ,Miller D ,Youl B , et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992;42:60-63
Web of Science | Medline12
Barkhof F ,Valk J ,Hommes OR ,Scheltens P ,Nauta JJ . Gadopentetate dimeglumine enhancement of multiple sclerosis lesions on long TR spin-echo images at 0.6 T. AJNR Am J Neuroradiol 1992;13:1257-1259
Web of Science | Medline13
Yednock TA ,Cannon C ,Fritz LC ,Sanchez-Madrid F ,Steinman L ,Karin N . Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992;356:63-66
CrossRef | Web of Science | Medline14
Kent SJ ,Karlik SJ ,Cannon C , et al. A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 1995;58:1-10
CrossRef | Web of Science | Medline15
Kent S ,Karlik S ,Rice GPA ,Horner H . A monoclonal antibody to alpha-4 integrin reverses the MRI detectable signs of experimental allergic encephalomyelitis in the guinea pig. Proc Int Soc Magn Reson Imaging 1994;3:1400-140016
Tubridy N ,Behan PO ,Capildeo R , et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. Neurology 1999;53:466-472
Web of Science | Medline17
Poser CM ,Paty DW ,Scheinberg L , et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231
CrossRef | Web of Science | Medline18
Lublin FD ,Reingold SC . Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911
CrossRef | Web of Science | Medline19
Kurtzke JF . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452
CrossRef | Web of Science | Medline20
Grimaud J ,Lai M ,Thorpe J , et al. Quantification of MRI lesion load in multiple sclerosis: a comparison of three computer-assisted techniques. Magn Reson Imaging 1996;14:495-505
CrossRef | Web of Science | Medline21
Noether GE . Sample size determination for some common nonparametric tests. J Am Stat Assoc 1987;82:645-647
CrossRef | Web of Science22
Li DKB ,Paty DW . Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999;46:197-206
CrossRef | Web of Science | Medline23
Comi G ,Filippi M ,Wolinsky JS . European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-297
CrossRef | Web of Science | Medline24
Coles AJ ,Wing MG ,Molyneux P , et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46:296-304
CrossRef | Web of Science | Medline25
Adams CWM. A colour atlas of multiple sclerosis and other myelin disorders. London: Wolfe Medical, 1989.
26
Ghosh S ,Goldin E ,Gordon FH , et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32
Free Full Text | Web of Science | Medline
- Citing Articles (409)
Citing Articles
1
Maria Pia Sormani, Paolo Bruzzi. (2013) MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. The Lancet Neurology 12:7, 669-676
2
Svend T. Rietdijk, Geert R. D'Haens. (2013) Recent developments in the treatment of inflammatory bowel disease. Journal of Digestive Diseases 14:6, 282-287
3
Luisa Klotz, Heinz Wiendl. (2013) Monoclonal antibodies in neuroinflammatory diseases. Expert Opinion on Biological Therapy 13:6, 831-846
4
Joel P. Thompson, Amir Abdolahi, Katia Noyes. (2013) Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple Sclerosis. PharmacoEconomics 31:6, 455-469
5
Y-B Chen, C S Cutler. (2013) Biomarkers for acute GVHD: can we predict the unpredictable?. Bone Marrow Transplantation 48:6, 755-760
6
Ludwig Kappos, Paul W. O’Connor, Christopher H. Polman, Patrick Vermersch, Heinz Wiendl, Amy Pace, Annie Zhang, Christophe Hotermans. (2013) Clinical effects of natalizumab on multiple sclerosis appear early in treatment course. Journal of Neurology 260:5, 1388-1395
7
Edward Ashton, Jonathan Riek. (2013) Advanced MR techniques in multicenter clinical trials. Journal of Magnetic Resonance Imaging 37:4, 761-769
8
Adeola I. Oyebamiji, Trisha M. Finlay, Rachael M. Hough, Vahid Hoghooghi, Erin-Mai F. Lim, Connie H.Y. Wong, Shalina S. Ousman. (2013) Characterization of migration parameters on peripheral and central nervous system T cells following treatment of experimental allergic encephalomyelitis with CRYAB. Journal of Neuroimmunology
9
Mahmoud H Mosli, Brian G Feagan. (2013) Vedolizumab for Crohn's disease. Expert Opinion on Biological Therapy 13:3, 455-463
10
Naveen Mulakayala, Pallavi Rao, Javed Iqbal, Rakeshwar Bandichhor, Srinivas Oruganti. (2013) Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: A brief overview. European Journal of Medicinal Chemistry 60, 170-186
11
João Sargento-Freitas, Sonia Batista, Carmo Macario, Fernando Matias, Livia Sousa. (2013) Clinical predictors of an optimal response to natalizumab in multiple sclerosis. Journal of Clinical Neuroscience
12
Masaki Setoguchi, Shin Iimura, Yuuichi Sugimoto, Yoshiyuki Yoneda, Jun Chiba, Toshiyuki Watanabe, Fumihito Muro, Yutaka Iigo, Gensuke Takayama, Mika Yokoyama, Tomoe Taira, Misato Aonuma, Tohru Takashi, Atsushi Nakayama, Nobuo Machinaga. (2013) A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid. Bioorganic & Medicinal Chemistry 21:1, 42-61
13
S. Rossi, C. Motta, V. Studer, V. De Chiara, F. Barbieri, F. Monteleone, A. Fornasiero, G. Coarelli, G. Bernardi, G. Cutter, O. Stüve, M. Salvetti, D. Centonze. (2013) Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. European Journal of Neurology 20:1, 87-94
14
Sunita Venkateswaran, Brenda Banwell. (2013) Clinical trials in pediatric multiple sclerosis: overcoming the challenges. Clinical Investigation 3:1, 49-56
15
John Zajicek. Multiple sclerosis. Elsevier, 2013:461-470.
16
Jeremy Chataway, David H. Miller. (2013) Natalizumab Therapy for Multiple Sclerosis. Neurotherapeutics 10:1, 19-28
17
Alireza Minagar. (2013) Current and Future Therapies for Multiple Sclerosis. Scientifica 2013, 1-11
18
Thomas Simon, Sylvie Pogu, Virginie Tardif, Kevin Rigaud, Séverine Rémy, Eliane Piaggio, Jean-Marie Bach, Ignacio Anegon, Philippe Blancou. (2013) Carbon monoxide-treated dendritic cells decrease β1-integrin induction on CD8 + T cells and protect from type 1 diabetes. European Journal of Immunology 43:1, 209-218
19
Guglielmo Manenti, Simone Altobelli, Marco Nezzo, Marco Antonicoli, Erald Vasili, Luca Neroni, Roberto Floris, Giovanni Simonetti. (2013) Early Magnetic Resonance Detection of Natalizumab-Related Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Sclerosis. Case Reports in Radiology 2013, 1-8
20
Brenda L. Banwell. Pediatric multiple sclerosis. Elsevier, 2013:1263-1274.
21
V Foti Cuzzola, E Palella, D Celi, M Barresi, S Giacoppo, P Bramanti, S Marino. (2012) Pharmacogenomic update on multiple sclerosis: a focus on actual and new therapeutic strategies. The Pharmacogenomics Journal 12:6, 453-461
22
Aitor G. Granja, Francisco Carrillo-Salinas, Alberto Pagani, María Gómez-Cañas, Roberto Negri, Carmen Navarrete, Miriam Mecha, Leyre Mestre, Bend L. Fiebich, Irene Cantarero, Marco A. Calzado, Maria L. Bellido, Javier Fernandez-Ruiz, Giovanni Appendino, Carmen Guaza, Eduardo Muñoz. (2012) A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis. Journal of Neuroimmune Pharmacology 7:4, 1002-1016
23
Mahmoud H Mosli, Brian G Feagan. (2012) The emerging role of vedolizumab in the treatment of ulcerative colitis. Clinical Investigation 2:12, 1201-1212
24
Eric R. Fedyk, Tim Wyant, Li-Li Yang, Vilmos Csizmadia, Kristine Burke, Hua Yang, Vivek J. Kadambi. (2012) Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflammatory Bowel Diseases 18:11, 2107-2119
25
Eric Thouvenot, Bertrand Carlander, William Camu. (2012) Subcutaneous IFN-β1a to treat relapsing–remitting multiple sclerosis. Expert Review of Neurotherapeutics 12:11, 1283-1291
26
Y-B Chen, S McDonough, H Chen, J Kennedy, C Illiano, E C Attar, K K Ballen, B R Dey, S L McAfee, M Jagasia, R Soiffer, T R Spitzer, J Ritz. (2012) Expression of α4β7 integrin on memory CD8+ T cells at the presentation of acute intestinal GVHD. Bone Marrow Transplantation
27
O. Fernández, C. Oreja-Guevara, R. Arroyo, G. Izquierdo, J. L. Pérez, X. Montalban. (2012) Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study. Journal of Neurology 259:9, 1814-1823
28
Ropper , Allan H. , . (2012) Two Centuries of Neurology and Psychiatry in the Journal. New England Journal of Medicine 367:1, 58-65
Free Full Text29
René M. Vigeveno, Oliver T. Wiebenga, Mike P. Wattjes, Jeroen J.G. Geurts, Frederik Barkhof. (2012) Shifting imaging targets in multiple sclerosis: From inflammation to neurodegeneration. Journal of Magnetic Resonance Imaging 36:1, 1-19
30
Gary A Rosenberg. (2012) Neurological diseases in relation to the blood–brain barrier. Journal of Cerebral Blood Flow & Metabolism 32:7, 1139-1151
31
Prakash Manikwar, Paul Kiptoo, Ahmed H. Badawi, Barlas Büyüktimkin, Teruna J. Siahaan. (2012) Antigen-specific blocking of CD4-Specific immunological synapse formation using BPI and current therapies for autoimmune diseases. Medicinal Research Reviews 32:4, 727-764
32
Yan Gan, Ruolan Liu, Wei Wu, Roberto Bomprezzi, Fu-Dong Shi. (2012) Antibody to α4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 247:1-2, 9-15
33
J A Snowden, R Saccardi, M Allez, S Ardizzone, R Arnold, R Cervera, C Denton, C Hawkey, M Labopin, G Mancardi, R Martin, J J Moore, J Passweg, C Peters, M Rabusin, M Rovira, J M van Laar, D Farge. (2012) Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation 47:6, 770-790
34
Ian Craig Lawrance. (2012) Modifying T-cell trafficking to the intestinal as a potential management for inflammatory bowel disease. Expert Opinion on Investigational Drugs1-10
35
James M. Stankiewicz, Samia J. Khoury. Medication Treatment in Multiple Sclerosis. In: Multiple Sclerosis. Wiley-Blackwell, 2012:181-212.
36
Til Menge. (2012) Günstiger Einfluss auf die MRT-Aktivität nur in hoher Dosierung. InFo Neurologie & Psychiatrie 14:4, 39-42
37
D H Miller, D R Altmann, D T Chard. (2012) Advances in Imaging to Support the Development of Novel Therapies for Multiple Sclerosis. Clinical Pharmacology & Therapeutics
38
J Liu. (2012) Systematic review and meta-analysis of randomized controlled trials of Chinese herbal medicine in treatment of multiple sclerosis. Journal of Chinese Integrative Medicine 10:2, 141-153
39
Ulf Kallweit, Ilijas Jelcic, Nathalie Braun, Heike Fischer, Björn Zörner, Bettina Schreiner, Arseny A. Sokolov, Roland Martin, Michael Weller, Michael Linnebank. (2012) Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline. Clinical Neuropharmacology1
40
David H Miller, Thomas Weber, Richard Grove, Claire Wardell, Joseph Horrigan, Ole Graff, Gillian Atkinson, Pinky Dua, Tarek Yousry, David MacManus, Xavier Montalban. (2012) Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet Neurology 11:2, 131-139
41
Alexandre Prat, Olaf Stüve. (2012) Firategrast—natalizumab in a pill?. The Lancet Neurology 11:2, 120-121
42
Judit Füvesi, Cecilia Rajda, Krisztina Bencsik, József Toldi, László Vécsei. (2012) The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications. Journal of Neural Transmission
43
Y. Yu, J. Zhu, L.-Z. Mi, T. Walz, H. Sun, J. Chen, T. A. Springer. (2012) Structural specializations of 4 7, an integrin that mediates rolling adhesion. The Journal of Cell Biology 196:1, 131-146
44
Henrik Gensicke, David Leppert, Özgür Yaldizli, Raija L.P. Lindberg, Matthias Mehling, Ludwig Kappos, Jens Kuhle. (2012) Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis. CNS Drugs 26:1, 11-37
45
Annette Baumgartner, Oliver Stich, Sebastian Rauer. (2012) Clinical and Radiological Disease Reactivation After Cessation of Long-Term Therapy With Natalizumab. International Journal of Neuroscience 122:1, 35-39
46
Eiji Kawamoto, Susumu Nakahashi, Takayuki Okamoto, Hiroshi Imai, Motomu Shimaoka. (2012) Anti-Integrin Therapy for Multiple Sclerosis. Autoimmune Diseases 2012, 1-6
47
Rehab AlJamal-Naylor, Linda Wilson, Susan McIntyre, Fiona Rossi, Beth Harrison, Mark Marsden, David J. Harrison. (2012) Allosteric Modulation of Beta1 Integrin Function Induces Lung Tissue Repair. Advances in Pharmacological Sciences 2012, 1-16
48
Carola T. Murphy, Kenneth Nally, Fergus Shanahan, Silvia Melgar. (2012) Shining a Light on Intestinal Traffic. Clinical and Developmental Immunology 2012, 1-14
49
Carol Castaneda, Michael S. LaPointe. Gold Standard Animal Models. In: Pharmaceutical Sciences Encyclopedia. John Wiley & Sons, Inc., 2011.
50
Frederik Barkhof, Jack H. Simon, Franz Fazekas, Marco Rovaris, Ludwig Kappos, Nicola de Stefano, Chris H. Polman, John Petkau, Ernst W. Radue, Maria P. Sormani, David K. Li, Paul O'Connor, Xavier Montalban, David H. Miller, Massimo Filippi. (2011) MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nature Reviews Neurology
51
I. Ifergan, H. Kebir, J. I. Alvarez, G. Marceau, M. Bernard, L. Bourbonniere, J. Poirier, P. Duquette, P. J. Talbot, N. Arbour, A. Prat. (2011) Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on 4 integrin. Brain 134:12, 3557-3574
52
Masaki Setoguchi, Shin Iimura, Yuuichi Sugimoto, Yoshiyuki Yoneda, Jun Chiba, Toshiyuki Watanabe, Fumihito Muro, Yutaka Iigo, Gensuke Takayama, Mika Yokoyama, Tomoe Taira, Misato Aonuma, Tohru Takashi, Atsushi Nakayama, Nobuo Machinaga. (2011) Identification of trans-4-[1-[[7-fluoro-2-(1-methyl-3-indolyl)-6-benzoxazolyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid as a potent, orally active VLA-4 antagonist. Bioorganic & Medicinal Chemistry
53
Yanbo Zhang, Hongyan Wang. (2011) Integrin signaling and function in immune cells. Immunologyno-no
54
Franziska Petermann, Thomas Korn. (2011) Cytokines and effector T cell subsets causing autoimmune CNS disease. FEBS Letters 585:23, 3747-3757
55
Pietro Iaffaldano, Guglielmo Lucchese, Maria Trojano. (2011) Treating multiple sclerosis with natalizumab. Expert Review of Neurotherapeutics 11:12, 1683-1692
56
Alexander Zarbock, Tibor Kempf, Kai C. Wollert, Dietmar Vestweber. (2011) Leukocyte integrin activation and deactivation: novel mechanisms of balancing inflammation. Journal of Molecular Medicine
57
Oscar Fernández. (2011) Nuevos fármacos para el tratamiento de la esclerosis múltiple. FMC - Formación Médica Continuada en Atención Primaria 18:9, 582-588
58
Eugenio Pucci, Giorgio Giuliani, Alessandra Solari, Silvana Simi, Silvia Minozzi, Carlo Di Pietrantonj, Ian Galea, Eugenio Pucci. Natalizumab for relapsing remitting multiple sclerosis. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2011.
59
María José Magraner, Francisco Coret, Arantxa Navarré, Isabel Boscá, María Simó, Matilde Escutia, Ana Bernad, Laura Navarro, Bonaventura Casanova. (2011) Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study. Journal of Neurology 258:10, 1805-1811
60
Lola Weiss, Reuven Or, Richard C. Jones, Ravi Amunugama, Lellean JeBailey, Sivakumar Ramu, Steven A. Bernstein, Zhanna Yekhtin, Osnat Almogi-Hazan, Reut Shainer, Alexander O. Vortmeyer, Michael J. Paidas, Michael Zeira, Shimon Slavin, Eytan R. Barnea, Israel Reibstein. (2011) Preimplantation Factor (PIF*) reverses neuroinflammation while promoting neural repair in EAE model. Journal of the Neurological Sciences
61
Todd V. Cartee, Kellie J. White, Marvin Newton-West, Robert A. Swerlick. (2011) Hypoxia and hypoxia mimetics inhibit TNF-dependent VCAM1 induction in the 5A32 endothelial cell line via a hypoxia inducible factor dependent mechanism. Journal of Dermatological Science
62
A. Kerbrat, E. Le Page, E. Leray, T. Anani, M. Coustans, C. Desormeaux, C. Guiziou, P. Kassiotis, F. Lallement, D. Laplaud, P. Diraison, F. Rouhart, E. Sartori, R. Wardi, S. Wiertlewski, G. Edan. (2011) Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients. Journal of the Neurological Sciences 308:1-2, 98-102
63
Ander Abarrategi, Luis Mariñas-Pardo, Isabel Mirones, Esther Rincón, Javier García-Castro. (2011) Mesenchymal niches of bone marrow in cancer. Clinical and Translational Oncology 13:9, 611-616
64
Stephen M Schaaf, David Pitt, Michael K Racke. (2011) What happens when natalizumab therapy is stopped?. Expert Review of Neurotherapeutics 11:9, 1247-1250
65
Bahareh Ajami, Jami L Bennett, Charles Krieger, Kelly M McNagny, Fabio M V Rossi. (2011) Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nature Neuroscience 14:9, 1142-1149
66
A. Horga, M. Tintoré. (2011) Natalizumab para la esclerosis múltiple remitente-recurrente. Neurología 26:6, 357-368
67
Nan Hu, Johanna Westra, Cees G.M. Kallenberg. (2011) Dysregulated neutrophil–endothelial interaction in antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides: Implications for pathogenesis and disease intervention. Autoimmunity Reviews 10:9, 536-543
68
Erica Seiguer Shenoy, Eleftherios Mylonakis, Rocio M. Hurtado, Nagagopal Venna. (2011) Natalizumab and HSV meningitis. Journal of NeuroVirology 17:3, 288-290
69
Toshimitsu Uede. (2011) Osteopontin, intrinsic tissue regulator of intractable inflammatory diseases. Pathology International 61:5, 265-280
70
Nancy L. Sicotte. (2011) Magnetic Resonance Imaging in Multiple Sclerosis: The Role of Conventional Imaging. Neurologic Clinics 29:2, 343-356
71
Andrea Harrer, Peter Wipfler, Max Einhaeupl, Georg Pilz, Katrin Oppermann, Wolfgang Hitzl, Shahrzad Afazel, Elisabeth Haschke-Becher, Peter Strasser, Eugen Trinka, Joerg Kraus. (2011) Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells. Journal of Neuroimmunology 234:1-2, 148-154
72
Eduardo J. Villablanca, Barbara Cassani, Ulrich H. von Andrian, J. Rodrigo Mora. (2011) Blocking Lymphocyte Localization to the Gastrointestinal Mucosa as a Therapeutic Strategy for Inflammatory Bowel Diseases. Gastroenterology 140:6, 1776-1784.e5
73
Ruth Lyck, Roberta Martinelli. (2011) Mechanisms of T-cell migration across the BBB. Future Neurology 6:3, 375-388
74
Michael P. Czech, Myriam Aouadi, Gregory J. Tesz. (2011) RNAi-based therapeutic strategies for metabolic disease. Nature Reviews Endocrinology 7:8, 473-484
75
G. Martin-Blondel, P. Delobel, A. Blancher, P. Massip, B. Marchou, R. S. Liblau, L. T. Mars. (2011) Pathogenesis of the immune reconstitution inflammatory syndrome affecting the central nervous system in patients infected with HIV. Brain 134:4, 928-946
76
Cris S Constantinescu, Nasr Farooqi, Kate O'Brien, Bruno Gran. (2011) Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). British Journal of Pharmacologyno-no
77
Amy E. Lovett-Racke, Yuhong Yang, Michael K. Racke. (2011) Th1 versus Th17: Are T cell cytokines relevant in multiple sclerosis?. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1812:2, 246-251
78
Timothy W West, Bruce Cree. (2011) Is there a role for planned natalizumab dosage suspension in mitigating progressive multifocal leukoencephalopathy risk?. Neurodegenerative Disease Management 1:1, 11-14
79
Ajay Nirula, Scott M Glaser, Susan L Kalled, Frederick R Taylora. (2011) What is IgG4? A review of the biology of a unique immunoglobulin subtype. Current Opinion in Rheumatology 23:1, 119-124
80
M. G. Marrosu, L. Lorefice, J. Frau, G. Coghe, G. Fenu, R. Piras, M. Melis, E. Cocco. (2011) The cohort of the multiple sclerosis center of Cagliari. Neurological Sciences 31:S3, 309-312
81
Makiko N Mieno, Takuhiro Yamaguchi, Yasuo Ohashi. (2011) Alternative statistical methods for estimating efficacy of interferon beta-1b for multiple sclerosis clinical trials. BMC Medical Research Methodology 11:1, 80
82
A. Horga, M. Tintoré. (2011) Natalizumab for relapsing-remitting multiple sclerosis. Neurología (English Edition) 26:6, 357-368
83
Igal Ifergan, Hania Kebir, Simone Terouz, Jorge I. Alvarez, Marc-André Lécuyer, Steve Gendron, Lyne Bourbonnière, Ildiko R. Dunay, Alain Bouthillier, Robert Moumdjian, Adriano Fontana, Arsalan Haqqani, Armelle Klopstein, Marco Prinz, Rubèn López-Vales, Thomas Birchler, Alexandre Prat. (2011) Role of Ninjurin-1 in the migration of myeloid cells to CNS inflammatory lesions. Annals of Neurologyn/a-n/a
84
Eileen M. O’Connor, Rae Ann Maxwell. Clinical Development and Benefit–Risk Profile of Natalizumab. In: Neuroinflammation. Elsevier, 2011:167-191.
85
Joost Smolders, Jan Damoiseaux. Vitamin D as a T-cell Modulator in Multiple Sclerosis. Elsevier, 2011:401-428.
86
Silvia Melgar, Fergus Shanahan. (2010) Inflammatory bowel disease—From mechanisms to treatment strategies. Autoimmunity 43:7, 463-477
87
Clare J. Fowler, Catherine Dalton, Jalesh N. Panicker. (2010) Review of Neurologic Diseases for the Urologist. Urologic Clinics of North America 37:4, 517-526
88
Ailsa L. Hart, Siew C. Ng, Elizabeth Mann, Hafid Omar Al-Hassi, David Bernardo, Stella C. Knight. (2010) Homing of immune cells: Role in homeostasis and intestinal inflammation. Inflammatory Bowel Diseases 16:11, 1969-1977
89
M. Filippi, M. A. Rocca, D. L. Arnold, R. Bakshi, F. Barkhof, N. De Stefano, F. Fazekas, E. Frohman, D. H. Miller, J. S. Wolinsky. Use of Imaging in Multiple Sclerosis. In: European Handbook of Neurological Management. Wiley-Blackwell, 2010:35-51.
90
D. T. Selewski, G. V. Shah, B. M. Segal, P. A. Rajdev, S. K. Mukherji. (2010) Natalizumab (Tysabri). American Journal of Neuroradiology 31:9, 1588-1590
91
Alban Millonig, Harald Hegen, Franziska Di Pauli, Rainer Ehling, Claudia Gneiss, Martina Hoelzl, Bettina Künz, Andreas Lutterotti, Dagmar Rudzki, Thomas Berger, Markus Reindl, Florian Deisenhammer. (2010) Natalizumab treatment reduces endothelial activity in MS patients. Journal of Neuroimmunology 227:1-2, 190-194
92
Ikuo Tsunoda, Robert S. Fujinami. (2010) Neuropathogenesis of Theiler’s Murine Encephalomyelitis Virus Infection, An Animal Model for Multiple Sclerosis. Journal of Neuroimmune Pharmacology 5:3, 355-369
93
J.J. Graber, C.A. McGraw, D. Kimbrough, S. Dhib-Jalbut. (2010) Overlapping and distinct mechanisms of action of multiple sclerosis therapies. Clinical Neurology and Neurosurgery 112:7, 583-591
94
Timothy W. West, Bruce A.C. Cree. (2010) Natalizumab dosage suspension: Are we helping or hurting?. Annals of Neurology 68:3, 395-399
95
Alexei Y. Savinov, Paul Burn. (2010) Interference with islet-specific homing of autoreactive T cells: an emerging therapeutic strategy for type 1 diabetes. Drug Discovery Today 15:13-14, 531-539
96
C. Cordiglieri, F. Odoardi, B. Zhang, M. Nebel, N. Kawakami, W. E. F. Klinkert, D. Lodygin, F. Luhder, E. Breunig, D. Schild, V. K. Ulaganathan, K. Dornmair, W. Dammermann, B. V. L. Potter, A. H. Guse, A. Flugel. (2010) Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system. Brain 133:7, 1930-1943
97
Robert B. Nussenblatt, Bibiana Bielekova, Richard Childs, Alan Krensky, Warren Strober, Giorgio Trinchieri, . (2010) National Institutes of Health Center for Human Immunology Conference, September 2009. Annals of the New York Academy of Sciences 1200, E1-E23
98
Gijs Kooij, Jack van Horssen, Elizabeth C.M. de Lange, Arie Reijerkerk, Susanne M.A. van der Pol, Bert van het Hof, Joost Drexhage, Anke Vennegoor, Joep Killestein, George Scheffer, Ruud Oerlemans, Rik Scheper, Paul van der Valk, Christine D. Dijkstra, Helga E. de Vries. (2010) T lymphocytes impair P-glycoprotein function during neuroinflammation. Journal of Autoimmunity 34:4, 416-425
99
Fernanda Pinto-Mariz, Luciana Rodrigues Carvalho, Wallace de Mello, Alexandra de Queiroz Campos Araújo, Márcia Gonçalves Ribeiro, Maria do Carmo Soares Alves Cunha, Thomas Voit, Gillian Butler-Browne, Suse Dayse Silva-Barbosa, Wilson Savino. (2010) Differential integrin expression by T lymphocytes: Potential role in DMD muscle damage. Journal of Neuroimmunology 223:1-2, 128-130
100
Reza Vosoughi, Mark S. Freedman. (2010) Therapy of MS. Clinical Neurology and Neurosurgery 112:5, 365-385
101
Nicholas H. Hunt, Georges E. Grau, Christian Engwerda, Scott R. Barnum, Henri van der Heyde, Diana S. Hansen, Louis Schofield, Jacob Golenser. (2010) Murine cerebral malaria: the whole story. Trends in Parasitology 26:6, 272-274
102
Yoshikazu Takada, Yoko Ono, Jun Sagusa, Constantine Mitsiades, Nicholas Mitsiades, Jean Tsai, Yong He, Ernest Maningding, Annie Coleman, Dalila Ramirez-Maverakis, Raphael Rodriquez, Yoko Takada, Emanual Maverakis. (2010) A T cell-binding fragment of fibrinogen can prevent autoimmunity. Journal of Autoimmunity 34:4, 453-459
103
Xianzhen Hu, Scott R. Barnum, Jillian E. Wohler, Trenton R. Schoeb, Daniel C. Bullard. (2010) Differential ICAM-1 isoform expression regulates the development and progression of experimental autoimmune encephalomyelitis. Molecular Immunology 47:9, 1692-1700
104
Ernst-Wilhelm Radue, William H. Stuart, Peter A. Calabresi, Christian Confavreux, Steven L. Galetta, Richard A. Rudick, Fred D. Lublin, Bianca Weinstock-Guttman, Daniel R. Wynn, Elizabeth Fisher, Athina Papadopoulou, Frances Lynn, Michael A. Panzara, Alfred W. Sandrock. (2010) Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. Journal of the Neurological Sciences 292:1-2, 28-35
105
Daniel Wynn, Michael Kaufman, Xavier Montalban, Timothy Vollmer, Jack Simon, Jacob Elkins, Gilmore O'Neill, Lauri Neyer, James Sheridan, Chungchi Wang, Alice Fong, John W Rose. (2010) Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. The Lancet Neurology 9:4, 381-390
106
S. Y. Lim, C. S. Constantinescu. (2010) Current and future disease-modifying therapies in multiple sclerosis. International Journal of Clinical Practice 64:5, 637-650
107
Amer Awad, Olaf Stüve. (2010) Multiple Sclerosis in the Elderly Patient. Drugs & Aging 27:4, 283-294
108
Michael Bennett, Robert Heard. (2010) Hyperbaric Oxygen Therapy for Multiple Sclerosis. CNS Neuroscience & Therapeutics 16:2, 115-124
109
Roland Martin. (2010) Multiple sclerosis: Closing in on an oral treatment. Nature 464:7287, 360-362
110
Joan B. O'Sullivan, Karen M. Ryan, Andrew Harkin, Thomas J. Connor. (2010) Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge. Journal of Neuroimmunology 220:1-2, 34-42
111
Lucienne Chatenoud. (2010) Immune therapy for type 1 diabetes mellitus—what is unique about anti-CD3 antibodies?. Nature Reviews Endocrinology 6:3, 149-157
112
Devon Conway, Jeffrey A Cohen. (2010) Combination therapy in multiple sclerosis. The Lancet Neurology 9:3, 299-308
113
Sunita Venkateswaran, Brenda Banwell. (2010) Pediatric Multiple Sclerosis. The Neurologist 16:2, 92-105
114
Thomas S. Reger, Jasmine Zunic, Nicholas Stock, Bowei Wang, Nicholas D. Smith, Benito Munoz, Mitchell D. Green, Michael F. Gardner, Joyce P. James, Weichao Chen, Kenneth Alves, Qian Si, Kelly M. Treonze, Russell B. Lingham, Richard A. Mumford. (2010) Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists. Bioorganic & Medicinal Chemistry Letters 20:3, 1173-1176
115
Edward Ashton. (2010) Quantitative MR in multi-center clinical trials. Journal of Magnetic Resonance Imaging 31:2, 279-288
116
Jillian E. Wohler, Sherry S. Smith, Scott R. Barnum. (2010)
T cells: The overlooked T-cell subset in demyelinating disease. Journal of Neuroscience Research 88:1, 1-6
117
Jochen Guck, Franziska Lautenschläger, Stephan Paschke, Michael Beil. (2010) Critical review: cellular mechanobiology and amoeboid migration. Integrative Biology 2:11-12, 575
118
Masaaki Niino, Hidenao Sasaki. (2010) Update on the treatment options for multiple sclerosis. Expert Review of Clinical Immunology 6:1, 77-88
119
M. Kelly Nicholas, Rimas Lukas. Immunologic Privilege and the Brain. Elsevier, 2010:169-181.
120
Jerry S. Wolinsky, Tzippy Shochat, Sivan Weiss, David Ladkani. (2009) Glatiramer acetate treatment in PPMS: Why males appear to respond favorably. Journal of the Neurological Sciences 286:1-2, 92-98
121
Lindå , Hans , von Heijne , Anders , Major , Eugene O. , Ryschkewitsch , Caroline , Berg , Johan , Olsson , Tomas , Martin , Claes , . (2009) Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy. New England Journal of Medicine 361:11, 1081-1087
Free Full Text122
Kelly M. Treonze, Kenneth Alves, Paul Fischer, William K. Hagmann, Donald Hora, Alison Kulick, Ken Vakerich, Nicholas D. Smith, Russell B. Lingham, Salony Maniar. (2009) Characterization of α4β1 (CD49d/CD29) on equine leukocytes: Potential utility of a potent α4β1 (CD49d/CD29) receptor antagonist in the treatment of equine heaves (recurrent airway obstruction). Veterinary Immunology and Immunopathology 130:1-2, 79-87
123
Nicole A. Belmar, John R. Lombardo, Debra T. Chao, Olga Li, Xiaohong Ma, Melody Pong-Afar, Debbie A. Law, Gary C. Starling. (2009) Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model. Journal of Neuroimmunology 212:1-2, 65-73
124
Bert A. ‘t Hart, Rogier Q. Hintzen, Jon D. Laman. (2009) Multiple sclerosis – a response-to-damage model. Trends in Molecular Medicine 15:6, 235-244
125
Nancy G. Wehner, Carolyn Gasper, George Shopp, Joyce Nelson, Ken Draper, Suezanne Parker, Janet Clarke. (2009) Immunotoxicity profile of natalizumab. Journal of Immunotoxicology 6:2, 115-129
126
Lawrence Steinman. (2009) A molecular trio in relapse and remission in multiple sclerosis. Nature Reviews Immunology 9:6, 440-447
127
John W. Rose, John F. Foley, Noel G. Carlson. (2009) Monoclonal antibody treatments for multiple sclerosis. Current Treatment Options in Neurology 11:3, 211-220
128
Jeffrey L. Bennett, Olaf Stüve. (2009) Update on Inflammation, Neurodegeneration, and Immunoregulation in Multiple Sclerosis. Clinical Neuropharmacology 32:3, 121-132
129
J Ludovic Croxford, Takashi Yamamura. (2009) Back to the future for multiple sclerosis therapy: focus on current and emerging disease-modifying therapeutic strategies. Immunotherapy 1:3, 403-423
130
Nicolas Weiss, Florence Miller, Sylvie Cazaubon, Pierre-Olivier Couraud. (2009) The blood-brain barrier in brain homeostasis and neurological diseases. Biochimica et Biophysica Acta (BBA) - Biomembranes 1788:4, 842-857
131
Takashi Ito, Masayuki Takahashi, Kenichi Sudo, Yuichi Sugiyama. (2009) Interindividual pharmacokinetics variability of the α 4 β 1 integrin antagonist, 4-[1-[3-Chloro-4-[N′-(2-methylphenyl)ureido]phenylacetyl]-(4 S )-fluoro-(2 S )-pyrrolidine-2-yl]methoxybenzoic acid (D01-4582), in beagles is associated with albumin genetic polymorphisms. Journal of Pharmaceutical Sciences 98:4, 1545-1555
132
Laurie J. Barten, Douglas R. Allington, Kendra A. Procacci, Michael P. Rivey. (2009) Natalizumab update: a story of benefit and risk. Drug Discovery Today: Therapeutic Strategies 6:1, 21-31
133
, M. Hutchinson, L. Kappos, P. A. Calabresi, C. Confavreux, G. Giovannoni, S. L. Galetta, E. Havrdova, F. D. Lublin, D. H. Miller, P. W. O’Connor, J. T. Phillips, C. H. Polman, E.-W. Radue, R. A. Rudick, W. H. Stuart, A. Wajgt, B. Weinstock-Guttman, D. R. Wynn, F. Lynn, M. A. Panzara. (2009) The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. Journal of Neurology 256:3, 405-415
134
Maria Pia Sormani, Laura Bonzano, Luca Roccatagliata, Gary R. Cutter, Gian Luigi Mancardi, Paolo Bruzzi. (2009) Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta-analytic approach. Annals of Neurology 65:3, 268-275
135
Fumihito Muro, Shin Iimura, Yoshiyuki Yoneda, Jun Chiba, Toshiyuki Watanabe, Masaki Setoguchi, Gensuke Takayama, Mika Yokoyama, Tohru Takashi, Atsushi Nakayama, Nobuo Machinaga. (2009) A novel and potent VLA-4 antagonist based on trans-4-substituted cyclohexanecarboxylic acid. Bioorganic & Medicinal Chemistry 17:3, 1232-1243
136
Eugenio Pucci, Giorgio Giuliani, Alessandra Solari, Carlo Di Pietrantonj, Silvana Simi, Silvia Minozzi, Ian Galea, Eugenio Pucci. Natalizumab for relapsing remitting multiple sclerosis. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2009.
137
Koyu Ito, Shigeyuki Kon, Yosuke Nakayama, Daisuke Kurotaki, Yoshinari Saito, Masashi Kanayama, Chiemi Kimura, HongYan Diao, Junko Morimoto, Yutaka Matsui, Toshimitsu Uede. (2009) The differential amino acid requirement within osteopontin in α4 and α9 integrin-mediated cell binding and migration. Matrix Biology 28:1, 11-19
138
Manfred Kunz, Saleh M. Ibrahim. (2009) Cytokines and Cytokine Profiles in Human Autoimmune Diseases and Animal Models of Autoimmunity. Mediators of Inflammation 2009, 1-20
139
Woojun Kim, Ho Jin Kim. (2009) Multiple Sclerosis. Journal of the Korean Medical Association 52:7, 665
140
David H. Broide, P. Sriramarao. Cellular Adhesion in Inflammation. In: Middleton's Allergy: Principles and Practice. Elsevier, 2009:149-164.
141
Dean Sheppard. Adhesion Molecules in Asthma and Airway Diseases. In: Asthma and COPD. Elsevier, 2009:257-263.
142
Eun Jeong Park, Motomu Shimaoka. Chapter 4 Activation of Leukocyte Integrins. Elsevier, 2009:115-132.
143
P. S. Rommer, O. Stüve, R. Goertsches, E. Mix, U. K. Zettl. (2008) Monoclonal antibodies in the therapy of multiple sclerosis. Journal of Neurology 255:S6, 28-35
144
Olaf Stüve, Ralf Gold, Andrew Chan, Eilhard Mix, Uwe Zettl, Bernd C. Kieseier. (2008) α4-Integrin antagonism with natalizumab. Journal of Neurology 255:S6, 58-65
145
Georg Pilz, Peter Wipfler, Gunther Ladurner, Jörg Kraus. (2008) Modern multiple sclerosis treatment – what is approved, what is on the horizon. Drug Discovery Today 13:23-24, 1013-1025
146
Fumihito Muro, Shin Iimura, Yoshiyuki Yoneda, Jun Chiba, Toshiyuki Watanabe, Masaki Setoguchi, Yutaka Iigou, Gensuke Takayama, Mika Yokoyama, Tohru Takashi, Atsushi Nakayama, Nobuo Machinaga. (2008) Identification of 4-[1-[3-chloro-4-[N’-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist. Bioorganic & Medicinal Chemistry 16:23, 9991-10000
147
Ralf A. Linker, Bernd C. Kieseier, Ralf Gold. (2008) Identification and development of new therapeutics for multiple sclerosis. Trends in Pharmacological Sciences 29:11, 558-565
148
Richard J. Davenport, James R. Munday. (2008) Blocking α4-integrins — A small molecule approach to treatment of multiple sclerosis. Journal of the Neurological Sciences 274:1-2, 27-30
149
Cristina Maria Costantino, Clare Baecher-Allan, David A. Hafler. (2008) Multiple Sclerosis and Regulatory T Cells. Journal of Clinical Immunology 28:6, 697-706
150
R.A. Linker, B.C. Kieseier. (2008) Therapieentscheidungen bei Multipler Sklerose. Der Nervenarzt 79:10, 1123-1134
151
William J. Karpus, Nathaneal Reynolds, Heather A. Behanna, Linda J. Van Eldik, D. Martin Watterson. (2008) Inhibition of experimental autoimmune encephalomyelitis by a novel small molecular weight proinflammatory cytokine suppressing drug. Journal of Neuroimmunology 203:1, 73-78
152
, H. Wiendl, K. V. Toyka, P. Rieckmann, R. Gold, H.-P. Hartung, R. Hohlfeld. (2008) Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations. Journal of Neurology 255:10, 1449-1463
153
Rodabe N. Amaria, John R. Corboy, Christina A. Finlayson, William A. Robinson, Virginia F. Borges. (2008) Immunomodulatory Therapy in Multiple Sclerosis and Breast Cancer Risk: A Case Report and Literature Review. Clinical Breast Cancer 8:5, 449-452
154
C. Infante-Duarte, S. Waiczies, J. Wuerfel, F. Zipp. (2008) New developments in understanding and treating neuroinflammation. Journal of Molecular Medicine 86:9, 975-985
155
John W. Rose, John Foley, Noel Carlson. (2008) Monoclonal antibody treatments for multiple sclerosis. Current Neurology and Neuroscience Reports 8:5, 419-426
156
Federica Sallusto, Marco Baggiolini. (2008) Chemokines and leukocyte traffic. Nature Immunology 9:9, 949-952
157
Benjamin M Segal, Cris S Constantinescu, Aparna Raychaudhuri, Lilianne Kim, Rosanne Fidelus-Gort, Lloyd H Kasper. (2008) Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. The Lancet Neurology 7:9, 796-804
158
Gian Luigi Mancardi, Maria Pia Amato, Roberto D’Alessandro, Filippo Drago, Clara Milanese, Patrizia Popoli, Leandro Provinciali, Pasqualino Rossi, Giovanni Savettieri, Gioacchino Tedeschi, Maria Rosaria Tola, Nicola Vanacore, Anna Covezzoli, Marisa Rosa, Carlo Piccinni, Nicola Montanaro, Laura Periotto, Antonio Addis, Nello Martini. (2008) Natalizumab: a country-based surveillance program. Neurological Sciences 29:S2, 235-237
159
Shane M Devlin, Remo Panaccione. (2008) Adalimumab for the treatment of Crohn's disease. Expert Opinion on Biological Therapy 8:7, 1011-1019
160
Omar Khan, Yimin Shen, Fen Bao, Christina Caon, Alexandros Tselis, Zahid Latif, Imad Zak. (2008) Long-Term Study of Brain 1 H-MRS Study in Multiple Sclerosis: Effect of Glatiramer Acetate Therapy on Axonal Metabolic Function and Feasibility of Long-Term 1 H-MRS Monitoring in Multiple Sclerosis. Journal of Neuroimaging 18:3, 314-319
161
David J. Phillips, Richard J. Davenport, Thierry A. Demaude, Fiona P. Galleway, Mark W. Jones, Laurent Knerr, Benjamin G. Perry, Andrew J. Ratcliffe. (2008) Imidazopyridines as VLA-4 integrin antagonists. Bioorganic & Medicinal Chemistry Letters 18:14, 4146-4149
162
Phillip G. Popovich, Erin E. Longbrake. (2008) Can the immune system be harnessed to repair the CNS?. Nature Reviews Neuroscience 9:6, 481-493
163
Raktima Bhattacharya, Berit Osburg, Dagmar Fischer, Ulrich Bickel. (2008) Targeted Delivery of Complexes of Biotin–PEG–Polyethylenimine and NF-κB Decoys to Brain-derived Endothelial Cells in Vitro. Pharmaceutical Research 25:3, 605-615
164
Woo-Yong Lee, Paul Kubes. (2008) Leukocyte adhesion in the liver: Distinct adhesion paradigm from other organs. Journal of Hepatology 48:3, 504-512
165
Aaron Boster, Gilles Edan, Elliott Frohman, Adil Javed, Olaf Stuve, Alexandros Tselis, Howard Weiner, Bianca Weinstock-Guttman, Omar Khan. (2008) Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. The Lancet Neurology 7:2, 173-183
166
Osamu Saku, Kiminori Ohta, Eri Arai, Yuji Nomoto, Hiroko Miura, Hiroaki Nakamura, Eiichi Fuse, Yoshisuke Nakasato. (2008) Synthetic study of VLA-4/VCAM-1 inhibitors: Synthesis and structure–activity relationship of piperazinylphenylalanine derivatives. Bioorganic & Medicinal Chemistry Letters 18:3, 1053-1057
167
Antonella Viola, Andrew D. Luster. (2008) Chemokines and Their Receptors: Drug Targets in Immunity and Inflammation. Annual Review of Pharmacology and Toxicology 48:1, 171-197
168
Yong Gong, J. Kent Barbay, Edward S. Kimball, Rosemary J. Santulli, M. Carolyn Fisher, Alexey B. Dyatkin, Tamara A. Miskowski, Pamela J. Hornby, Wei He. (2008) Synthesis and SAR of pyridazinone-substituted phenylalanine amide α4 integrin antagonists. Bioorganic & Medicinal Chemistry Letters 18:4, 1331-1335
169
Raija L.P. Lindberg, Lutz Achtnichts, Francine Hoffmann, Jens Kuhle, Ludwig Kappos. (2008) Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. Journal of Neuroimmunology 194:1-2, 153-164
170
An-Rong Li, Michael G. Johnson, Jiwen Liu, Xiaoqi Chen, Xiaohui Du, Jeffrey T. Mihalic, Jeffrey Deignan, Darin J. Gustin, Jason Duquette, Zice Fu, Liusheng Zhu, Andrew P. Marcus, Phillipe Bergeron, Lawrence R. McGee, Jay Danao, Bryan Lemon, Teresa Carabeo, Timothy Sullivan, Ji Ma, Liang Tang, George Tonn, Tassie L. Collins, Julio C. Medina. (2008) Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists. Bioorganic & Medicinal Chemistry Letters 18:2, 688-693
171
Alexander Zarbock, Klaus Ley. (2008) Mechanisms and Consequences of Neutrophil Interaction with the Endothelium. The American Journal of Pathology 172:1, 1-7
172
Benjamin Leader, Quentin J. Baca, David E. Golan. (2008) Protein therapeutics: a summary and pharmacological classification. Nature Reviews Drug Discovery 7:1, 21-39
173
Til Menge, Martin S Weber, Bernhard Hemmer, Bernd C Kieseier, Hans-Christian von Büdingen, Clemens Warnke, Scott S Zamvil, Aaron Boster, Omar Khan, Hans-Peter Hartung, Olaf Stüve. (2008) Disease-Modifying Agents for Multiple Sclerosis. Drugs 68:17, 2445-2468
174
Michael H. Bennett, Robert J. Turner, DipDHM, Jan P. Lehm, Herbert B. Newton. Evidence and Hyperbaric Oxygen Therapy. In: Physiology and Medicine of Hyperbaric Oxygen Therapy. Elsevier, 2008:451-510.
175
K. A. Owen, F. J. Pixley, K. S. Thomas, M. Vicente-Manzanares, B. J. Ray, A. F. Horwitz, J. T. Parsons, H. E. Beggs, E. R. Stanley, A. H. Bouton. (2007) Regulation of lamellipodial persistence, adhesion turnover, and motility in macrophages by focal adhesion kinase. The Journal of Cell Biology 179:6, 1275-1287
176
K. Ohkuma, T. Sasaki, S. Kamei, S. Okuda, H. Nakano, T. Hamamoto, K. Fujihara, I. Nakashima, T. Misu, Y. Itoyama. (2007) Modulation of dendritic cell development by immunoglobulin G in control subjects and multiple sclerosis patients. Clinical & Experimental Immunology 150:3, 397-406
177
R. Gold, P. Rieckmann. (2007) Fortschritte im Verständnis von Pathogenese und Immuntherapie der Multiplen Sklerose. Der Nervenarzt 78:S1, 15-26
178
C. Kleinschnitz, S. G. Meuth, O. Stüve, B. Kieseier, H. Wiendl. (2007) Multiple sclerosis therapy: An update on recently finished trials. Journal of Neurology 254:11, 1473-1490
179
Domenico Fiore. (2007) Multiple Sclerosis and Natalizumab. American Journal of Therapeutics 14:6, 555-560
180
Paolo A. Muraro, Bibiana Bielekova. (2007) Emerging therapies for multiple sclerosis. Neurotherapeutics 4:4, 676-692
181
Luisa Klotz, Linda Diehl, Indra Dani, Harald Neumann, Nanette von Oppen, Andreas Dolf, Elmar Endl, Thomas Klockgether, Britta Engelhardt, Percy Knolle. (2007) Brain endothelial PPARγ controls inflammation-induced CD4+ T cell adhesion and transmigration in vitro. Journal of Neuroimmunology 190:1-2, 34-43
182
Richard A. Rudick, Deborah Miller, Steve Hass, Michael Hutchinson, Peter A. Calabresi, Christian Confavreux, Steven L. Galetta, Gavin Giovannoni, Eva Havrdova, Ludwig Kappos, Fred D. Lublin, David H. Miller, Paul W. O'Connor, J. Theodore Phillips, Chris H. Polman, Ernst-Wilhelm Radue, William H. Stuart, Andrzej Wajgt, Bianca Weinstock-Guttman, Daniel R. Wynn, Frances Lynn, Michael A. Panzara. (2007) Health-related quality of life in multiple sclerosis: effects of natalizumab. Annals of Neurology 62:4, 335-346
183
Hin Hin Ko, Brian Bressler. (2007) Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn’s disease. Expert Review of Gastroenterology & Hepatology 1:1, 29-39
184
References. In: Statistical Thinking for Non-Statisticians in Drug Regulation. John Wiley & Sons, Ltd, 2007:261-266.
185
Stephen D. Miller, Danielle M. Turley, Joseph R. Podojil. (2007) Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nature Reviews Immunology 7:9, 665-677
186
C. Kleinschnitz, S.G. Meuth, B.C. Kieseier, H. Wiendl. (2007) Multiple-Sklerose-Update zur Pathophysiologie und neuen immuntherapeutischen Ansätzen. Der Nervenarzt 78:8, 883-911
187
Stuart D. Cook. (2007) Approved drugs and their problems in patient care: Routes of administration and dosing. Journal of the Neurological Sciences 259:1-2, 38-41
188
Kenneth P. Johnson. (2007) Natalizumab (Tysabri) Treatment for Relapsing Multiple Sclerosis. The Neurologist 13:4, 182-187
189
Michael D. Carrithers, Lisette M. Carrithers, Jan Czyzyk, Octavian Henegariu. (2007) Characterization of a severe parenchymal phenotype of experimental autoimmune encephalomyelitis in (C57BL6xB10.PL)F1 mice. Journal of Neuroimmunology 187:1-2, 31-43
190
Dean M Wingerchuk, Claudia F Lucchinetti. (2007) Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. Current Opinion in Neurology 20:3, 343-350
191
Bernd C Kieseier, Heinz Wiendl, Bernhard Hemmer, Hans-Peter Hartung. (2007) Treatment and treatment trials in multiple sclerosis. Current Opinion in Neurology 20:3, 286-293
192
F. Tarantini, I. Baiardini, G. Passalacqua, F. Braido, G. W. Canonica. (2007) Asthma treatment: ?magic bullets which seek their own targets?. Allergy 62:6, 605-610
193
Daniel C. Bullard, Xianzhen Hu, Jillian E. Adams, Trenton R. Schoeb, Scott R. Barnum. (2007) p150/95 (CD11c/CD18) Expression Is Required for the Development of Experimental Autoimmune Encephalomyelitis. The American Journal of Pathology 170:6, 2001-2008
194
A. M. O’Rourke, E. Y. Wang, L. Salter-Cid, L. Huang, A. Miller, E. Podar, H. F. Gao, D. S. Jones, M. D. Linnik. (2007) Benefit of inhibiting SSAO in relapsing experimental autoimmune encephalomyelitis. Journal of Neural Transmission 114:6, 845-849
195
Anthony Traboulsee. (2007) MRI relapses have significant pathologic and clinical implications in multiple sclerosis. Journal of the Neurological Sciences 256, S19-S22
196
Simon F Lacey, Wendi Zhou. (2007) Immune responses to BK and JC viruses in immunocompromised patients. Future Virology 2:3, 255-266
197
Stephan R. Targan, Brian G. Feagan, Richard N. Fedorak, Bret A. Lashner, Remo Panaccione, Daniel H. Present, Martina E. Spehlmann, Paul J. Rutgeerts, Zsolt Tulassay, Miroslava Volfova, Douglas C. Wolf, Chito Hernandez, Jeffrey Bornstein, William J. Sandborn. (2007) Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial. Gastroenterology 132:5, 1672-1683
198
Michael Hutchinson. (2007) Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Therapeutics and Clinical Risk Management 3:2, 259-268
199
. Fernndez Fernndez, V.E. Fernndez. (2007) Tratamiento de la esclerosis m?ltiple. Tratamiento de los brotes. Tratamiento de fondo. Esteroides. Inmunosupresores. Interfer?n beta. Indicaciones. Posolog?a. Contraindicaciones. Efectos secundarios. Criterios de asociaci?n. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 9:76, 4878-4885
200
Lawrence Samkoff, Andrew Goodman. Disease-modifying therapy for multiple sclerosis in clinical practice. In: Multiple Sclerosis Therapeutics, Third Edition. CRC Press, 2007:723-749.
201
Jerry Wolinsky. The multiple sclerosis disease process as characterized by magnetic resonance imaging. In: Multiple Sclerosis Therapeutics, Third Edition. CRC Press, 2007:45-63.
202
John Noseworthy. The challenge of long-term studies in multiple sclerosis. In: Multiple Sclerosis Therapeutics, Third Edition. CRC Press, 2007:319-330.
203
Aaron Miller. Ethical considerations in multiple sclerosis clinical trials. In: Multiple Sclerosis Therapeutics, Third Edition. CRC Press, 2007:343-356.
204
Kazuhiko Yamamoto, Akiko Okamoto, Keishi Fujio. (2007) Antigen-specific immunotherapy for autoimmune diseases. Expert Opinion on Biological Therapy 7:3, 359-367
205
Gert van Assche. (2007) Emerging drugs to treat Crohn’s disease. Expert Opinion on Emerging Drugs 12:1, 49-59
206
Olaf Stüve, Jeffrey L. Bennett. (2007) Pharmacological Properties, Toxicology and Scientific Rationale for the use of Natalizumab (Tysabri
207
Derek Soon, Daniel R. Altmann, Kryshani T.M. Fernando, Garin Giovannoni, Frederick Barkhof, Chris H. Polman, Paul O’Connor, Bruce Gray, Michael Panzara, David H. Miller. (2007) A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis. Journal of Neurology 254:3, 306-314
208
Jun Chiba, Shin Iimura, Yoshiyuki Yoneda, Toshiyuki Watanabe, Fumito Muro, Masao Tsubokawa, Yutaka Iigou, Atsushi Satoh, Gensuke Takayama, Mika Yokoyama, Tohru Takashi, Atsushi Nakayama, Nobuo Machinaga. (2007) Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists. Bioorganic & Medicinal Chemistry 15:4, 1679-1693
209
John K MacDonald, John WD McDonald, John K MacDonald. Natalizumab for induction of remission in Crohn's disease. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2007.
210
Ikuo Tsunoda, Emily Jane Terry, Benjamin J. Marble, Elias Lazarides, Catherine Woods, Robert S. Fujinami. (2007) Modulation of Experimental Autoimmune Encephalomyelitis by VLA-2 Blockade. Brain Pathology 17:1, 45-55
211
Ratna Prasad, Shailendra Giri, Narender Nath, Inderjit Singh, Avtar K. Singh. (2007) GSNO attenuates EAE disease byS-nitrosylation-mediated modulation of endothelial-monocyte interactions. Glia 55:1, 65-77
212
A. Verma. (2007) Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis. Yearbook of Neurology and Neurosurgery 2007, 83-84
213
Paul O’Connor. (2007) Natalizumab and the role of α 4 -integrin antagonism in the treatment of multiple sclerosis. Expert Opinion on Biological Therapy 7:1, 123-136
214
Thomas M. Zollner, Khusru Asadullah, Michael P. Schön. (2007) Targeting leukocyte trafficking to inflamed skin - still an attractive therapeutic approach?. Experimental Dermatology 16:1, 1-12
215
Istvan Pirko, John H. Noseworthy. Demyelinating Disorders of the Central Nervous System. In: Textbook of Clinical Neurology. Elsevier, 2007:1103-1133.
216
Brian P. Bosworth, Brian R. Landzberg. Neurological manifestations of gastrointestinal and hepatic diseases. In: Neurobiology of Disease. Elsevier, 2007:689-701.
217
Bernhard Hemmer, Nicole Töpfner, Hans-Peter Hartung. Immunopathogenesis of multiple sclerosis. In: Neurobiology of Disease. Elsevier, 2007:197-204.
218
Kevin Rostásy. Multiple Sclerosis in Children: Clinical, Diagnostic, and Therapeutic Aspects. Elsevier, 2007:269-279.
219
Alireza Minagar, April Carpenter, J. Steven Alexander. The Destructive Alliance: Interactions Of Leukocytes, Cerebral Endothelial Cells, and the Immune Cascade in Pathogenesis of Multiple Sclerosis. Elsevier, 2007:1-11.
220
Volker Siffrin, Alexander U. Brandt, Josephine Herz, Frauke Zipp. New Insights into Adaptive Immunity in Chronic Neuroinflammation. Elsevier, 2007:1-40.
221
Tanuja Chitnis. The Role of CD4 T Cells in the Pathogenesis of Multiple Sclerosis. Elsevier, 2007:43-72.
222
Elena Korniychuk, John M. Dempster, Eileen O'Connor, J. Steven Alexander, Roger E. Kelley, Meghan Kenner, Uma Menon, Vivek Misra, Romy Hoque, Eduardo Gonzalez‐Toledo, Robert N. Schwendimann, Stacy Smith, Alireza Minagar. Evolving Therapies For Multiple Sclerosis. Elsevier, 2007:571-588.
223
Smriti M. Agrawal, V. Wee Yong. Immunopathogenesis of Multiple Sclerosis. Elsevier, 2007:99-126.
224
Lucienne Chatenoud. (2006) Immune therapies of autoimmune diseases: are we approaching a real cure?. Current Opinion in Immunology 18:6, 710-717
225
Angela S. Archambault, Julia Sim, Erin E. McCandless, Robyn S. Klein, John H. Russell. (2006) Region-specific regulation of inflammation and pathogenesis in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 181:1-2, 122-132
226
, Peter Rieckmann. (2006) Immunmodulatorische Stufentherapie der Multiplen Sklerose. Der Nervenarzt 77:12, 1506-1518
227
Hartmut Wekerle, Florian C. Kurschus. (2006) Animal models of multiple sclerosis. Drug Discovery Today: Disease Models 3:4, 359-367
228
Allen J. Aksamit. (2006) Review of Progressive Multifocal Leukoencephalopathy and Natalizumab. The Neurologist 12:6, 293-298
229
Robert Weissert. (2006) The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived. Expert Review of Neurotherapeutics 6:11, 1587-1590
230
Acute Coronary Syndrome: NSTEMI. In: Wiley Handbook of Current and Emerging Drug Therapies. John Wiley & Sons, Inc., 2006.
231
Paulus Mrass, Wolfgang Weninger. (2006) Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors. Immunological Reviews 213:1, 195-212
232
Peter Vanderslice, Darren G Woodside. (2006) Integrin antagonists as therapeutics for inflammatory diseases. Expert Opinion on Investigational Drugs 15:10, 1235-1255
233
Nicole C. Kaneider, Andrew J. Leger, Athan Kuliopulos. (2006) Therapeutic targeting of molecules involved in leukocyte?endothelial cell interactions. FEBS Journal 273:19, 4416-4424
234
William W. Agace. (2006) Tissue-tropic effector T cells: generation and targeting opportunities. Nature Reviews Immunology 6:9, 682-692
235
Martin Stangel, Refik Pul. (2006) Basic principles of intravenous immunoglobulin (IVIg) treatment. Journal of Neurology 253:S5, v18-v24
236
Peter Rieckmann. (2006) Socio-economic aspects of neuroimmunological diseases. Journal of Neurology 253:S5, v87-v90
237
Jörg Kraus, Patrick Oschmann. (2006) The impact of interferon-β treatment on the blood–brain barrier. Drug Discovery Today 11:15-16, 755-762
238
Igor J. Koralnik. (2006) Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?. Annals of Neurology 60:2, 162-173
239
Jürgen Drews. (2006) Case histories, magic bullets and the state of drug discovery. Nature Reviews Drug Discovery 5:8, 635-640
240
Russell E Bartt. (2006) Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy. Current Opinion in Neurology 19:4, 341-349
241
T. Holmoy, A. L. K. Hestvik, F. Vartdal. (2006) Management of progressive multifocal leukoencephalopathy associated with natalizumab – possibilities and responsibility. European Journal of Neurology 13:8, e2-e2
242
David-Axel Laplaud, Laureline Berthelot, Patrick Miqueu, Kasia Bourcier, Julien Moynard, Yannick Oudinet, Marina Guillet, Catherine Ruiz, Neal Oden, Sophie Brouard, Charles R.G. Guttmann, Howard L. Weiner, Samia J. Khoury, Jean-Paul Soulillou. (2006) Serial blood T cell repertoire alterations in multiple sclerosis patients; correlation with clinical and MRI parameters. Journal of Neuroimmunology 177:1-2, 151-160
243
Akira Goto, Yoshiaki Arimura, Yasuhisa Shinomura, Kohzoh Imai, Yuji Hinoda. (2006) Antisense therapy of MAdCAM-1 for trinitrobenzenesulfonic acid-induced murine colitis. Inflammatory Bowel Diseases 12:8, 758-765
244
JK MacDonald, JWD McDonald, John MacDonald. Natalizumab for induction of remission in Crohn's disease. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2006.
245
Gert Van Assche, S??verine Vermeire, Paul Rutgeerts. (2006) Safety issues with biological therapies for inflammatory bowel disease. Current Opinion in Gastroenterology 22:4, 370???376
246
Jean Sibilia. (2006) Les biothérapies immunomodulatrices: Une révolution thérapeutique dans les maladies auto-immunes. Revue Francophone des Laboratoires 2006:384, 34-39
247
Bruce Cree. (2006) Emerging Monoclonal Antibody Therapies for Multiple Sclerosis. The Neurologist 12:4, 171-178
248
Bernhard Hemmer, Eiliot Frohman, Hans Peter Hartung, Olaf Stüve. (2006) Central nervous system infections – a potential complication of systemic immunotherapy. Current Opinion in Neurology 19:3, 271-276
249
Michael H Barnett, Ian Sutton. (2006) The pathology of multiple sclerosis: a paradigm shift. Current Opinion in Neurology 19:3, 242-247
250
Thomas Misgeld, Martin Kerschensteiner. (2006) In vivo imaging of the diseased nervous system. Nature Reviews Neuroscience 7:6, 449-463
251
Masaaki Niino, Caroline Bodner, Marie-Lune Simard, Sudabeh Alatab, Dawn Gano, Ho Jin Kim, Manuela Trigueiro, Denise Racicot, Christine Guérette, Jack P. Antel, Alyson Fournier, Francois Grand'Maison, Amit Bar-Or. (2006) Natalizumab effects on immune cell responses in multiple sclerosis. Annals of Neurology 59:5, 748-754
252
Stephen L. Hauser, Howard L. Weiner. (2006) Natalizumab: Immune effects and implications for therapy. Annals of Neurology 59:5, 731-732
253
Olaf Stüve, Christina M. Marra, Keith R. Jerome, Linda Cook, Petra D. Cravens, Sabine Cepok, Elliot M. Frohman, J. Theodore Phillips, Gabriele Arendt, Bernhard Hemmer, Nancy L. Monson, Michael K. Racke. (2006) Immune surveillance in multiple sclerosis patients treated with natalizumab. Annals of Neurology 59:5, 743-747
254
Sandeep K Agarwal, Michael B Brenner. (2006) Role of adhesion molecules in synovial inflammation. Current Opinion in Rheumatology 18:3, 268-276
255
Christopher P. Stowell. (2006) Therapy With Immunoglobulin. Journal of Infusion Nursing 29:Supplement, S29-S44
256
Victoria Pham, William J. Henzel, David Arnott, Sarah Hymowitz, Wendy N. Sandoval, Bao-Tran Truong, Henry Lowman, Jennie R. Lill. (2006) De novo proteomic sequencing of a monoclonal antibody raised against OX40 ligand. Analytical Biochemistry 352:1, 77-86
257
Philip F Stahel, Scott R Barnum. (2006) The role of the complement system in CNS inflammatory diseases. Expert Review of Clinical Immunology 2:3, 445-456
258
Francesco Lolli, Paolo Rovero, Mario Chelli, Anna Maria Papini. (2006) Toward biomarkers in multiple sclerosis: new advances. Expert Review of Neurotherapeutics 6:5, 781-794
259
Sylvia Delgado, William A. Sheremata. (2006) The role of CD4+ T-cells in the development of MS. Neurological Research 28:3, 245-249
260
B. Engelhardt. (2006) Molecular mechanisms involved in T cell migration across the blood–brain barrier. Journal of Neural Transmission 113:4, 477-485
261
Dorothée Chabas, Ari J. Green, Emmanuelle Waubant. (2006) Pediatric multiple sclerosis. NeuroRX 3:2, 264-275
262
Joseph R. Berger, Sidney Houff. (2006) Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab. Neurological Research 28:3, 299-305
263
Jun Chiba, Gensuke Takayama, Tohru Takashi, Mika Yokoyama, Atsushi Nakayama, John J. Baldwin, Edward McDonald, Kevin J. Moriarty, Christopher R. Sarko, Kurt W. Saionz, Robert Swanson, Zahid Hussain, Angela Wong, Nobuo Machinaga. (2006) Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists. Bioorganic & Medicinal Chemistry 14:8, 2725-2746
264
Marinos C. Dalakas. (2006) Therapeutic targets in patients with inflammatory myopathies: Present approaches and a look to the future. Neuromuscular Disorders 16:4, 223-236
265
Douglas S. Goodin. (2006) Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: Have we been overly harsh in our assessment?. Annals of Neurology 59:4, 597-605
266
Angela Bauch, Giulio Superti-Furga. (2006) Charting protein complexes, signaling pathways, and networks in the immune system. Immunological Reviews 210:1, 187-207
267
Anne H. Cross, Michael J. Ramsbottom, Jeri-Anne Lyons. (2006) NOS2 regulates cytokine production and VLA-4 expression in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 173:1-2, 79-86
268
M. Filippi, M. A. Rocca, D. L. Arnold, R. Bakshi, F. Barkhof, N. De Stefano, F. Fazekas, E. Frohman, J. S. Wolinsky. (2006) EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. European Journal of Neurology 13:4, 313-325
269
Frohman , Elliot M. , Racke , Michael K. , Raine , Cedric S. , . (2006) Multiple Sclerosis — The Plaque and Its Pathogenesis. New England Journal of Medicine 354:9, 942-955
Full Text270
Rudick , Richard A. , Stuart , William H. , Calabresi , Peter A. , Confavreux , Christian , Galetta , Steven L. , Radue , Ernst-Wilhelm , Lublin , Fred D. , Weinstock-Guttman , Bianca , Wynn , Daniel R. , Lynn , Frances , Panzara , Michael A. , Sandrock , Alfred W. , . (2006) Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis. New England Journal of Medicine 354:9, 911-923
Free Full Text271
Ropper , Allan H. , . (2006) Selective Treatment of Multiple Sclerosis. New England Journal of Medicine 354:9, 965-967
Full Text272
Polman , Chris H. , O'Connor , Paul W. , Havrdova , Eva , Hutchinson , Michael , Kappos , Ludwig , Miller , David H. , Phillips , J. Theodore , Lublin , Fred D. , Giovannoni , Gavin , Wajgt , Andrzej , Toal , Martin , Lynn , Frances , Panzara , Michael A. , Sandrock , Alfred W. , . (2006) A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. New England Journal of Medicine 354:9, 899-910
Free Full Text273
Joshua R. Korzenik, Daniel K. Podolsky. (2006) Evolving knowledge and therapy of inflammatory bowel disease. Nature Reviews Drug Discovery 5:3, 197-209
274
Dean M Wingerchuk. (2006) Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management. Expert Review of Neurotherapeutics 6:3, 333-346
275
Taro Hino, Takanori Yokota, Shingo Ito, Kazutaka Nishina, Young-Sook Kang, Shinobu Mori, Satoko Hori, Takashi Kanda, Tetsuya Terasaki, Hidehiro Mizusawa. (2006) In vivo delivery of small interfering RNA targeting brain capillary endothelial cells. Biochemical and Biophysical Research Communications 340:1, 263-267
276
Chris Ramsey, Signe Hässler, Per Marits, Olle Kämpe, Charles D. Surh, Leena Peltonen, Ola Winqvist. (2006) Increased antigen presenting cell-mediated T cell activation in mice and patients without the autoimmune regulator. European Journal of Immunology 36:2, 305-317
277
Jun Chiba, Shin Iimura, Yoshiyuki Yoneda, Yuichi Sugimoto, Takao Horiuchi, Fumito Muro, Yuichi Ochiai, Tomomi Ogasawara, Masao Tsubokawa, Yutaka Iigou, Gensuke Takayama, Tomoe Taira, Yoshimi Takata, Mika Yokoyama, Tohru Takashi, Atsushi Nakayama, Nobuo Machinaga. (2006) 4-(Pyrrolidinyl)methoxybenzoic Acid Derivatives as a Potent, Orally Active VLA-4 Antagonist. CHEMICAL & PHARMACEUTICAL BULLETIN 54:11, 1515-1529
278
Oren N. Gottfried, David H. Viskochil, Daniel W. Fults, William T. Couldwell. (2006) Molecular, Genetic, and Cellular Pathogenesis of Neurofibromas and Surgical Implications. Neurosurgery 58:1, 1-16
279
Oliver Neuhaus, Bernd C. Kieseier, Hans-Peter Hartung. (2006) Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacology & Therapeutics 109:1-2, 198-209
280
Dorothée Chabas, Ari J. Green, Emmanuelle Waubant. (2006) Pediatric multiple sclerosis. Neurotherapeutics 3:2, 264
281
Noel G Carlson, John W Rose. (2006) Antioxidants in Multiple Sclerosis. CNS Drugs 20:6, 433-441
282
Theo Dingermann, Ilse Zündorf. (2006) Macromolecular Immunosuppressants. Biotechnology Journal 1:1, 47-57
283
References. In: McAlpine's Multiple Sclerosis. Elsevier, 2006:811-946.
284
Jack H. Simon. (2006) Update on Multiple Sclerosis. Radiologic Clinics of North America 44:1, 79-100
285
Lucienne Chatenoud. Emerging Therapies for Autoimmune Diseases. In: The Autoimmune Diseases. Elsevier, 2006:1063-1081.
286
Charles R. Mackay, Ulrich H. Von Andrian. Adhesion Molecules and Chemoattractants in the Pathogenesis and Treatment of Autoimmune Diseases. In: The Autoimmune Diseases. Elsevier, 2006:237-IX.
287
Britta Engelhardt. (2006) Immune cell migration across the blood–brain barrier: molecular mechanisms and therapeutic targeting. Future Neurology 1:1, 47-56
288
Donald E. Staunton, Mark L. Lupher, Robert Liddington, W. Michael Gallatin. Targeting Integrin Structure and Function in Disease. Elsevier, 2006:111-157.
289
Hans Lassmann. (2005) Mechanisms of multiple sclerosis. Drug Discovery Today: Disease Mechanisms 2:4, 447-452
290
Andrew D Luster, Ronen Alon, Ulrich H von Andrian. (2005) Immune cell migration in inflammation: present and future therapeutic targets. Nature Immunology 6:12, 1182-1190
291
Alexey B. Dyatkin, Yong Gong, Tamara A. Miskowski, Edward S. Kimball, Stephen M. Prouty, M. Carolyn Fisher, Rosemary J. Santulli, Craig R. Schneider, Nathaniel H. Wallace, Pamela J. Hornby, Craig Diamond, William A. Kinney, Bruce E. Maryanoff, Bruce P. Damiano, Wei He. (2005) Aza-bicyclic amino acid carboxamides as α4β1/α4β7 integrin receptor antagonists. Bioorganic & Medicinal Chemistry 13:24, 6693-6702
292
Sandborn , William J. , Colombel , Jean Frédéric , Enns , Roberts , Feagan , Brian G. , Hanauer , Stephen B. , Lawrance , Ian C. , Panaccione , Remo , Sanders , Martin , Schreiber , Stefan , Targan , Stephan , van Deventer , Sander , Goldblum , Ronald , Despain , Darrin , Hogge , Gary S. , Rutgeerts , Paul , . (2005) Natalizumab Induction and Maintenance Therapy for Crohn's Disease. New England Journal of Medicine 353:18, 1912-1925
Free Full Text293
Ralf A. Linker, Michael Reinhardt, Martin Bendszus, Gesa Ladewig, Andreas Briel, Michael Schirner, Mathias Mäurer, Peter Hauff. (2005) In vivo molecular imaging of adhesion molecules in experimental autoimmune encephalomyelitis (EAE). Journal of Autoimmunity 25:3, 199-205
294
Reinhard Hohlfeld, Hartmut Wekerle. (2005) Drug Insight: using monoclonal antibodies to treat multiple sclerosis. Nature Clinical Practice Neurology 1:1, 34-44
295
Rachel Farrell, Dominic Heaney, Gavin Giovannoni. (2005) Emerging therapies in multiple sclerosis. Expert Opinion on Emerging Drugs 10:4, 797-816
296
Cornelia Halin, J. Rodrigo Mora, Cenk Sumen, Ulrich H. von Andrian. (2005) IN VIVO IMAGING OF LYMPHOCYTE TRAFFICKING. Annual Review of Cell and Developmental Biology 21:1, 581-603
297
P.S. Piraino, T.A. Yednock, E.K. Messersmith, M.A. Pleiss, S.B. Freedman, R.R. Hammond, S.J. Karlik. (2005) Spontaneous remyelination following prolonged inhibition of α4 integrin in chronic EAE. Journal of Neuroimmunology 167:1-2, 53-63
298
David J. Virley. (2005) Developing therapeutics for the treatment of multiple sclerosis. NeuroRX 2:4, 638-649
299
Gert Van Assche, Séverine Vermeire, Paul Rutgeerts. (2005) Medical treatment of inflammatory bowel diseases. Current Opinion in Internal Medicine 4:5, 457-461
300
Merja Soilu-Hänninen, Mikko Laaksonen, Arno Hänninen, Juha-Pekka Erälinna, Martin Panelius. (2005) Downregulation of VLA-4 on T cells as a marker of long term treatment response to interferon beta-1a in MS. Journal of Neuroimmunology 167:1-2, 175-182
301
Mark Ballow. (2005) -ximab this and -zumab that! Has the magic bullet arrived in the new millennium of medicine and science?. Journal of Allergy and Clinical Immunology 116:4, 738-743
302
Merja Soilu-Hänninen, Mikko Laaksonen, Arno Hänninen. (2005) Hyaluronate receptor (CD44) and integrin α4 (CD49d) are up-regulated on T cells during MS relapses. Journal of Neuroimmunology 166:1-2, 189-192
303
Britta Engelhardt, Richard M. Ransohoff. (2005) The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends in Immunology 26:9, 485-495
304
Inga Osmers, Daniel C. Bullard, Scott R. Barnum. (2005) PSGL-1 is not required for development of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 166:1-2, 193-196
305
Shankar Venkatraman, Jongwon Lim, Merryl Cramer, Michael F. Gardner, Joyce James, Kenneth Alves, Russell B. Lingham, Richard A. Mumford, Benito Munoz. (2005) Influence of acid surrogates toward potency of VLA-4 antagonist. Bioorganic & Medicinal Chemistry Letters 15:18, 4053-4056
306
Tetsuo Shiohara, Yoshiko Mizukawa, Jun Hayakawa, Kazuhito Hayakawa. (2005) T-cell dynamics of inflammatory skin diseases. Expert Review of Clinical Immunology 1:3, 357-368
307
Mark T Muir, Amy E Lovett-Racke, Michael K Racke. (2005) Novel therapeutic strategies targeting the pathogenic T-cells in multiple sclerosis. Expert Review of Clinical Immunology 1:3, 345-355
308
Norman J Kachuck. (2005) Challenges and opportunities: what we are learning from the clinical natalizumab experience. Expert Review of Neurotherapeutics 5:5, 605-615
309
Katarzyna Biernacki, Jack Antel. Immune Functions of Brain Endothelial Cells. In: The Blood-Brain Barrier and Its Microenvironment. CRC Press, 2005:167-191.
310
B. Schreiner, B. C. Kieseier, H.-P. Hartung, R. Hohlfeld, H. Wiendl. (2005) Blockade von Adhäsionsmolekülen mit Natalizumab in der Therapie der Multiplen Sklerose. Der Nervenarzt 76:8, 999-1005
311
M. Reinhardt, P. Hauff, R.A. Linker, A. Briel, R. Gold, P. Rieckmann, G. Becker, K.V. Toyka, M. Mäurer, M. Schirner. (2005) Ultrasound derived imaging and quantification of cell adhesion molecules in experimental autoimmune encephalomyelitis (EAE) by Sensitive Particle Acoustic Quantification (SPAQ). NeuroImage 27:2, 267-278
312
Kleinschmidt-DeMasters , B.K. , Tyler , Kenneth L. , . (2005) Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis. New England Journal of Medicine 353:4, 369-374
Free Full Text313
Van Assche , Gert , Van Ranst , Marc , Sciot , Raf , Dubois , Bénédicte , Vermeire , Séverine , Noman , Maja , Verbeeck , Jannick , Geboes , Karel , Robberecht , Wim , Rutgeerts , Paul , . (2005) Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease. New England Journal of Medicine 353:4, 362-368
Free Full Text314
Langer-Gould , Annette , Atlas , Scott W. , Green , Ari J. , Bollen , Andrew W. , Pelletier , Daniel , . (2005) Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab. New England Journal of Medicine 353:4, 375-381
Free Full Text315
Hans Lassmann. (2005) Multiple Sclerosis Pathology: Evolution of Pathogenetic Concepts. Brain Pathology 15:3, 217-222
316
Ilse Zündorf, Angelika M. Vollmar, Theo Dingermann. (2005) Makromolekulare Immunsuppressiva: Proteinogene Wirkstoffe. Pharmazie in unserer Zeit 34:4, 283-296
317
David N. Irani. (2005) Immunological mechanisms in multiple sclerosis. Clinical and Applied Immunology Reviews 5:4, 257-269
318
Feagan , Brian G. , Greenberg , Gordon R. , Wild , Gary , Fedorak , Richard N. , Paré , Pierre , McDonald , John W.D. , Dubé , Rejean , Cohen , Albert , Steinhart , A. Hillary , Landau , Steven , Aguzzi , Rasha A. , Fox , Irving H. , Vandervoort , Margaret K. , . (2005) Treatment of Ulcerative Colitis with a Humanized Antibody to the α4β7 Integrin. New England Journal of Medicine 352:24, 2499-2507
Free Full Text319
Marc Feldmann, Lawrence Steinman. (2005) Design of effective immunotherapy for human autoimmunity. Nature 435:7042, 612-619
320
Joep Killestein, Chris H Polman. (2005) Current trials in multiple sclerosis: established evidence and future hopes. Current Opinion in Neurology 18:3, 253-260
321
Barbara Garmy-Susini, Hui Jin, Yuhong Zhu, Rou-Jia Sung, Rosa Hwang, Judy Varner. (2005) Integrin α4β1–VCAM-1–mediated adhesion between endothelial and mural cells is required for blood vessel maturation. Journal of Clinical Investigation 115:6, 1542-1551
322
Bernd C Kieseier, Bernhard Hemmer, Hans-Peter Hartung. (2005) Multiple sclerosis – novel insights and new therapeutic strategies. Current Opinion in Neurology 18:3, 211-220
323
Eric T Wong. (2005) Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm. Expert Opinion on Pharmacotherapy 6:7, 1107-1114
324
Alexandre Prat, Jack Antel. (2005) Pathogenesis of multiple sclerosis. Current Opinion in Neurology 18:3, 225-230
325
Lawrence Steinman. (2005) Case history: Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nature Reviews Drug Discovery 4:6, 510-518
326
Basit Javaid, Richard J. Quigg. (2005) Treatment of glomerulonephritis: Will we ever have options other than steroids and cytotoxics?. Kidney International 67:5, 1692-1703
327
Cord Brakebusch. (2005) Commentary 5. Experimental Dermatology 14:5, 400-400
328
Ee Tuan Lim, Gavin Giovannoni. (2005) Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis. Expert Review of Neurotherapeutics 5:3, 379-390
329
Brenda Banwell. (2005) Treatment of children and adolescents with multiple sclerosis. Expert Review of Neurotherapeutics 5:3, 391-401
330
J. Graber, M. Zhan, D. Ford, F. Kursch, G. Francis, C. Bever, H. Panitch, P.A. Calabresi, S. Dhib-Jalbut. (2005) Interferon-β-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis. Journal of Neuroimmunology 161:1-2, 169-176
331
Faisal G. Qureshi, Cynthia Leaphart, Selma Cetin, Jun Li, Anatoly Grishin, Simon Watkins, Henri R. Ford, David J. Hackam. (2005) Increased expression and function of integrins in enterocytes by endotoxin impairs epithelial restitution. Gastroenterology 128:4, 1012-1022
332
David A. Hafler, Jacqueline M. Slavik, David E. Anderson, Kevin C. O'Connor, Philip De Jager, Clare Baecher-Allan. (2005) Multiple sclerosis. Immunological Reviews 204:1, 208-231
333
Rohit Bakshi, Alireza Minagar, Zeenat Jaisani, Jerry S. Wolinsky. (2005) Imaging of multiple sclerosis: Role in neurotherapeutics. NeuroRX 2:2, 277-303
334
Mireia Sospedra, Roland Martin. (2005) IMMUNOLOGY OF MULTIPLE SCLEROSIS*. Annual Review of Immunology 23:1, 683-747
335
S. McQuaid, J. Kirk. (2005) The blood–brain barrier in multiple sclerosis. International Congress Series 1277, 235-243
336
Marika Merinen, Heikki Irjala, Marko Salmi, Ilkka Jaakkola, Arno Hänninen, Sirpa Jalkanen. (2005) Vascular Adhesion Protein-1 Is Involved in Both Acute and Chronic Inflammation in the Mouse. The American Journal of Pathology 166:3, 793-800
337
Michael Platten, Lawrence Steinman. (2005) Multiple sclerosis: trapped in deadly glue. Nature Medicine 11:3, 252-253
338
Susan A. Gauthier, Guy J. Buckle, Howard L. Weiner. (2005) Immunosuppressive therapy for multiple sclerosis. Neurologic Clinics 23:1, 247-272
339
Anthony Traboulsee, Guojun Zhao, David K.B. Li. (2005) Neuroimaging in multiple sclerosis. Neurologic Clinics 23:1, 131-148
340
Melanie R. Ursell, Paul W. O'Connor. (2005) Natalizumab and other monoclonal antibodies. Neurologic Clinics 23:1, 233-246
341
Aaron E. Miller. (2005) Glatiramer acetate in the treatment of multiple sclerosis. Neurologic Clinics 23:1, 215-231
342
John H. Noseworthy, Peter Kirkpatrick. (2005) Fresh from the pipeline: Natalizumab. Nature Reviews Drug Discovery 4:2, 101-102
343
Patric Turowski, Peter Adamson, John Greenwood. (2005) Pharmacological Targeting of ICAM-1 Signaling in Brain Endothelial Cells: Potential for Treating Neuroinflammation. Cellular and Molecular Neurobiology 25:1, 153-170
344
Jingwu Zhang, George Hutton. (2005) Role of Magnetic Resonance Imaging and Immunotherapy in Treating Multiple Sclerosis*. Annual Review of Medicine 56:1, 273-302
345
M. Judith Eikelenboom, Joep Killestein, Thijs Izeboud, Nynke F. Kalkers, Paul A. Baars, Rene A.W. van Lier, Frederik Barkhof, Bernard M.J. Uitdehaag, Chris H. Polman. (2005) Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS. Journal of Neuroimmunology 158:1-2, 222-230
346
Michel Chofflon. (2005) Mechanisms of Action for Treatments in??Multiple Sclerosis. BioDrugs 19:5, 299-308
347
William A Sheremata, Alireza Minagar, J Steven Alexander, Timothy Vollmer. (2005) The Role of Alpha-4 Integrin in the Aetiology of Multiple Sclerosis. CNS Drugs 19:11, 909-922
348
Rohit Bakshi, Alireza Minagar, Zeenat Jaisani, Jerry S. Wolinsky. (2005) Imaging of multiple sclerosis: Role in neurotherapeutics. Neurotherapeutics 2:2, 277
349
Brian J. Nickoloff, Brian K. Bonish, Frank O. Nestle. (2005) Viewpoint 2. Experimental Dermatology 14:1, 72-74
350
Siobhan M Leary, Alan J Thompson. (2005) Primary Progressive Multiple Sclerosis. CNS Drugs 19:5, 369-376
351
Jun Chiba, Nobuo Machinaga, Tohru Takashi, Akio Ejima, Gensuke Takayama, Mika Yokoyama, Atsushi Nakayama, John J. Baldwin, Edward McDonald, Kurt W. Saionz, Robert Swanson, Zahid Hussain, Angela Wong. (2005) Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist. Bioorganic & Medicinal Chemistry Letters 15:1, 41-45
352
Magnhild Sandberg-Wollheim. (2005) Interferon-β 1a treatment for multiple sclerosis. Expert Review of Neurotherapeutics 5:1, 25-34
353
Robyn S. Klein, Joshua B. Rubin, Andrew D. Luster. Chemokines and Central Nervous System Physiology. Elsevier, 2005:159-187.
354
Federica Sallusto, Charles R Mackay. (2004) Chemoattractants and their receptors in homeostasis and inflammation. Current Opinion in Immunology 16:6, 724-731
355
Youssef Hijazi, Horst Welker, Albert E. Dorr, Jian-Ping Tang, Roger Blain, Louis M. Renzetti, Richat Abbas. (2004) Pharmacokinetics, Safety, and Tolerability of R411, a Dual α4β1-α4β7 Integrin Antagonist After Oral Administration at Single and Multiple Once-Daily Ascending Doses in Healthy Volunteers. The Journal of Clinical Pharmacology 44:12, 1368-1378
356
, P. Rieckmann, K. V. Toyka. (2004) Escalating immunotherapy of multiple sclerosis. Journal of Neurology 251:11, 1329-1339
357
Gail H. Marracci, Gabriel P. McKeon, Whitney E. Marquardt, Rolf W. Winter, Michael K. Riscoe, Dennis N. Bourdette. (2004) ? lipoic acid inhibits human T-cell migration: Implications for multiple sclerosis. Journal of Neuroscience Research 78:3, 362-370
358
Francis J Dumont. (2004) CTLA4-Ig fusion proteins: promise for improved therapy of transplant rejection and autoimmune diseases. Therapy 1:2, 289-304
359
Bruce S. Bochner. (2004) Adhesion molecules as therapeutic targets. Immunology and Allergy Clinics of North America 24:4, 615-630
360
Francis J Dumont. (2004) CTLA4–Ig fusion proteins: promise for improved therapy of transplant rejection and autoimmune diseases. Therapy 1:2, 289-304
361
Gavin Giovannoni. (2004) Optimising MS disease-modifying therapies: antibodies in perspective. Journal of Neurology 251:S5, v30-v35
362
Ludwig Kappos, Jens Kuhle, Achim Gass, Lutz Achtnichts, Ernst-Wilhelm Radue. (2004) Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?. Journal of Neurology 251:S5, v57-v64
363
Gordon Francis. (2004) Benefit-risk assessment of interferon-b therapy for relapsing multiple sclerosis. Expert Opinion on Drug Safety 3:4, 289-303
364
Ralf Gold, Richard M Ransohoff, Alfred Sandrock, Peter Rieckmann. (2004) The blood–brain barrier as target of multiple sclerosis research and therapy. Journal of Neuroimmunology 152:1-2, 1-4
365
Richard A Rudick, Alfred Sandrock. (2004) Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Review of Neurotherapeutics 4:4, 571-580
366
Mary Ann T Gimenez, Julia E Sim, John H Russell. (2004) TNFR1-dependent VCAM-1 expression by astrocytes exposes the CNS to destructive inflammation. Journal of Neuroimmunology 151:1-2, 116-125
367
Georgios I Papachristou, Scott Plevy. (2004) Novel biologics in inflammatory bowel disease. Gastroenterology Clinics of North America 33:2, 251-269
368
Bert A 't Hart, Sandra Amor, Margreet Jonker. (2004) Evaluating the validity of animal models for research into therapies for immune-based disorders. Drug Discovery Today 9:12, 517-524
369
Robyn S. Klein. (2004) Regulation of neuroinflammation: The role of CXCL10 in lymphocyte infiltration during autoimmune encephalomyelitis. Journal of Cellular Biochemistry 92:2, 213-222
370
P.A. Muraro, L. Liberati, L. Bonanni, A. Pantalone, C.M. Caporale, C. Iarlori, G. De Luca, D. Farina, A. Lugaresi, D. Gambi. (2004) Decreased integrin gene expression in patients with MS responding to interferon-β treatment. Journal of Neuroimmunology 150:1-2, 123-131
371
Daniela Galimberti, Nereo Bresolin, Elio Scarpini. (2004) Chemokine network in multiple sclerosis: role in pathogenesis and targeting for future treatments. Expert Review of Neurotherapeutics 4:3, 439-453
372
David H. Miller. (2004) Biomarkers and surrogate outcomes in neurodegenerative disease: Lessons from multiple sclerosis. NeuroRX 1:2, 284-294
373
Animesh Nandi, Pila Estess, Mark Siegelman. (2004) Bimolecular Complex between Rolling and Firm Adhesion Receptors Required for Cell Arrest. Immunity 20:4, 455-465
374
Ho Jin Kim, Katarzyna Biernacki, Alexandre Prat, Jack P Antel, Amit Bar-Or. (2004) Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients. Clinical Immunology 111:1, 38-46
375
Richard E Gonsette. (2004) A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis. Expert Opinion on Pharmacotherapy 5:4, 747-765
376
C. M. Poser. (2004) Multiple sclerosis trait: the premorbid stage of multiple sclerosis. A hypothesis. Acta Neurologica Scandinavica 109:4, 239-243
377
David A. Hafler. (2004) Multiple sclerosis. Journal of Clinical Investigation 113:6, 788-794
378
David A. Hafler. (2004) Multiple sclerosis. Journal of Clinical Investigation 113:6, 788-794
379
Peter Vanderslice, Ronald J Biediger, Darren G Woodside, Kurt L Berens, George W Holland, Richard A.F Dixon. (2004) Development of cell adhesion molecule antagonists as therapeutics for asthma and COPD. Pulmonary Pharmacology & Therapeutics 17:1, 1-10
380
Kenji OHMORI, Kei ADACHI, Haruhiko MANABE, Daisuke HARADA, Etsuo OHSHIMA. (2004) Recent development of new drugs for the treatment of allergic diseases. Folia Pharmacologica Japonica 123:5, 335-348
381
&NA;. (2004) Natalizumab. Drugs in R & D 5:2, 102-107
382
Bianca Weinstock-Guttman, Rohit Bakshi. (2004) Combination Therapy for Multiple Sclerosis. CNS Drugs 18:12, 777-792
383
David H. Miller. (2004) Biomarkers and surrogate outcomes in neurodegenerative disease: Lessons from multiple sclerosis. NeuroRX 1:2, 284
384
Robert J Fox, Richard A Rudick. (2004) Multiple sclerosis: disease markers accelerate progress. The Lancet Neurology 3:1, 10
385
J.-C. Ouallet, B. Brochet. (2004) Aspects cliniques, physiopathologiques, et thérapeutiques de la sclérose en plaques. EMC - Neurologie 1:4, 1-27
386
Yang Feng-Chun, David A. Ingram, Shi Chen, Cynthia M. Hingtgen, Nancy Ratner, Kelly R. Monk, Travis Clegg, Hilary White, Laura Mead, Mary Jo Wenning, David A. Williams, Reuben Kapur, Simon J. Atkinson, D. Wade Clapp. (2003) Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/– mast cells. Journal of Clinical Investigation 112:12, 1851-1861
387
Yang Feng-Chun, David A. Ingram, Shi Chen, Cynthia M. Hingtgen, Nancy Ratner, Kelly R. Monk, Travis Clegg, Hilary White, Laura Mead, Mary Jo Wenning, David A. Williams, Reuben Kapur, Simon J. Atkinson, D. Wade Clapp. (2003) Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/– mast cells. Journal of Clinical Investigation 112:12, 1851-1861
388
Holger Ulbrich, Einar E Eriksson, Lennart Lindbom. (2003) Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends in Pharmacological Sciences 24:12, 640-647
389
Ghislain Opdenakker, Inge Nelissen, Jo Van Damme. (2003) Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. The Lancet Neurology 2:12, 747-756
390
Christopher B. Lock, Renu A. Heller. (2003) Gene microarray analysis of multiple sclerosis lesions. Trends in Molecular Medicine 9:12, 535-541
391
John Kirk, Jonnie Plumb, Meenakshi Mirakhur, Stephen McQuaid. (2003) Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. The Journal of Pathology 201:2, 319-327
392
Chris H Polman, Bernard MJ Uitdehaag. (2003) New and emerging treatment options for multiple sclerosis. The Lancet Neurology 2:9, 563-566
393
Pamela A McCombe. (2003) Gender issues in multiple sclerosis. Expert Review of Neurotherapeutics 3:5, 649-660
394
Pia Kivisäkk, Anne C. Cotleur, Jar-Chi Lee, Richard A. Rudick, Richard M. Ransohoff. (2003) Interferon-β1a does not reduce expression of CCR5 and CXCR3 on circulating T cells. Journal of Neuroimmunology 141:1-2, 150-154
395
Michael J. Holtzman. (2003) Drug Development for Asthma. American Journal of Respiratory Cell and Molecular Biology 29:2, 163-171
396
Bert A. ʼt Hart, Sandra Amor. (2003) The use of animal models to investigate the pathogenesis of neuroinflammatory disorders of the central nervous system. Current Opinion in Neurology 16:3, 375-383
397
P. Rutgeerts, S. Van Deventer, S. Schreiber. (2003) The expanding role of biological agents in the treatment of inflammatory bowel disease - focus on selective adhesion molecule inhibition. Alimentary Pharmacology and Therapeutics 17:12, 1435-1450
398
Scott S Zamvil, Lawrence Steinman. (2003) Diverse Targets for Intervention during Inflammatory and Neurodegenerative Phases of Multiple Sclerosis. Neuron 38:5, 685-688
399
Bernd C. Kieseier, Hans-Peter Hartung. (2003) Multiple paradigm shifts in multiple sclerosis. Current Opinion in Neurology 16:3, 247-252
400
Sheila A Doggrell. (2003) Is natalizumab a breakthrough in the treatment of multiple sclerosis?. Expert Opinion on Pharmacotherapy 4:6, 999-1001
401
John M Kovarik, Pascale Burtin. (2003) Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases. Expert Opinion on Emerging Drugs 8:1, 47-62
402
Emmanuelle Waubant. (2003) Emerging disease modifying therapies for multiple sclerosis. Expert Opinion on Emerging Drugs 8:1, 145-161
403
Jerry S Wolinsky. (2003) Rational therapy for relapsing multiple sclerosis. The Lancet Neurology 2:5, 271-272
404
(2003) Natalizumab for Relapsing Multiple Sclerosis. New England Journal of Medicine 348:16, 1598-1599
Free Full Text405
Lawrence Steinman. (2003) Medicine: Collateral damage repaired. Nature 422:6933, 671-672
406
Heinz Wiendl, Bernd C Kieseier. (2003) Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. Expert Opinion on Investigational Drugs 12:4, 689-712
407
Oliver Neuhaus, Juan J. Archelos, Hans-Peter Hartung. (2003) Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends in Pharmacological Sciences 24:3, 131-138
408
von Andrian , Ulrich H. , Engelhardt , Britta , . (2003) α4 Integrins as Therapeutic Targets in Autoimmune Disease. New England Journal of Medicine 348:1, 68-72
Full Text409
Teresa Español. (2003) Tratamiento con anticuerpos monoclonales. Medicina Clínica 121:2, 61-62
- Letters
